US20100029504A1 - Detecting pax2 for the diagnosis of breast cancer - Google Patents

Detecting pax2 for the diagnosis of breast cancer Download PDF

Info

Publication number
US20100029504A1
US20100029504A1 US12/546,292 US54629209A US2010029504A1 US 20100029504 A1 US20100029504 A1 US 20100029504A1 US 54629209 A US54629209 A US 54629209A US 2010029504 A1 US2010029504 A1 US 2010029504A1
Authority
US
United States
Prior art keywords
expression
pax2
defb1
cells
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US12/546,292
Other languages
English (en)
Inventor
Carlton D. Donald
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Medical University of South Carolina Foundation
Phigenix Inc
Original Assignee
Phigenix Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2008/051168 external-priority patent/WO2008089236A2/en
Application filed by Phigenix Inc filed Critical Phigenix Inc
Priority to US12/546,292 priority Critical patent/US20100029504A1/en
Priority to CN200980161426.2A priority patent/CN102648287B/zh
Priority to RU2012111372/10A priority patent/RU2522485C2/ru
Priority to JP2012526698A priority patent/JP2013510558A/ja
Priority to CA2771993A priority patent/CA2771993A1/en
Priority to NZ599004A priority patent/NZ599004A/en
Priority to AU2009351638A priority patent/AU2009351638B2/en
Priority to EP09848828.1A priority patent/EP2475779B1/en
Priority to PCT/US2009/054913 priority patent/WO2011025475A1/en
Priority to AP2012006182A priority patent/AP3331A/xx
Assigned to PHIGENIX, INC. reassignment PHIGENIX, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DONALD, CARLTON D.
Publication of US20100029504A1 publication Critical patent/US20100029504A1/en
Priority to CA2772036A priority patent/CA2772036A1/en
Priority to CN201410056507.9A priority patent/CN104083772A/zh
Priority to PCT/US2010/024740 priority patent/WO2011025556A1/en
Priority to RU2016133412A priority patent/RU2016133412A/ru
Priority to NZ599005A priority patent/NZ599005A/en
Priority to RU2012111271/15A priority patent/RU2012111271A/ru
Priority to EP20200194.7A priority patent/EP3811950A1/en
Priority to JP2012526740A priority patent/JP2013503162A/ja
Priority to EP10812443.9A priority patent/EP2470217B1/en
Priority to AP2012006181A priority patent/AP3412A/xx
Priority to CN2010800373971A priority patent/CN102481379A/zh
Priority to AU2010286924A priority patent/AU2010286924B2/en
Priority to US13/310,930 priority patent/US20120071347A1/en
Priority to IL218286A priority patent/IL218286A/en
Priority to IL218285A priority patent/IL218285A/en
Priority to ZA2012/02170A priority patent/ZA201202170B/en
Priority to ZA2012/02169A priority patent/ZA201202169B/en
Priority to US13/606,917 priority patent/US8722367B2/en
Priority to US13/607,040 priority patent/US8623617B2/en
Priority to HK13102262.2A priority patent/HK1174955A1/xx
Assigned to MEDICAL UNIVERSITY OF SOUTH CAROLINA reassignment MEDICAL UNIVERSITY OF SOUTH CAROLINA ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: DONALD, CARLTON D.
Assigned to MUSC FOUNDATION FOR RESEARCH DEVELOPMENT reassignment MUSC FOUNDATION FOR RESEARCH DEVELOPMENT ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: MEDICAL UNIVERSITY OF SOUTH CAROLINA
Priority to JP2015142631A priority patent/JP2016000041A/ja
Abandoned legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/142—Toxicological screening, e.g. expression profiles which identify toxicity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Definitions

  • the present application generally relates to medical diagnosis and, in particular, to methods for diagnosing cancerous conditions in various tissues.
  • Breast cancer is the most common cause of cancer in women and the second most common cause of cancer death in women in the U.S. While the majority of new breast cancers are diagnosed as a result of an abnormality seen on a mammogram, a lump or change in consistency of the breast tissue can also be a warning sign of the disease. Heightened awareness of breast cancer risk in the past decades has led to an increase in the number of women undergoing mammography for screening, leading to detection of cancers in earlier stages and a resultant improvement in survival rates. Still, breast cancer is the most common cause of death in women between the ages of 45 and 55.
  • Stage 0 is carcinoma (including lobular carcinoma and ductal carcinoma) in situ.
  • Stage I is an early stage of invasive breast cancer. The tumor is no more than 2 centimeters across. Cancer cells have not spread beyond the breast.
  • Stage II tumors include tumors that are no more than 2 centimeters across but has spread to the lymph nodes under the arm, tumors that are between 2 and 5 centimeters and may have spread to the lymph nodes under the arm, and tumors that are larger than 5 centimeters (2 inches) but has not spread to the lymph nodes under the arm.
  • Stage III is locally advanced cancer. It is further divided into Stage IIIA, IIIB, and IIIC.
  • Stage W is distant metastatic cancer. The cancer has spread to other parts of the body. Early-stage treatment options are different from late-stage options.
  • One aspect of the present invention relates to a method for monitoring breast conditions in a subject.
  • the method comprises determining a Paired Box 2 gene-to-beta defensin-1 gene (PAX2-to-DEFB1) expression ratio in cells obtained from the breast of the subject, wherein the PAX2-to-DEFB1 expression ratio is correlated with breast conditions and may serve as a prognosticator used for determining course of treatment.
  • PAX2-to-DEFB1 Paired Box 2 gene-to-beta defensin-1 gene
  • a PAX2-to-DEFB1 expression ratio of 100:1 or higher is indicative of the presence of breast cancer in the subject, and a PAX2-to-DEFB1 expression ratio less than 100:1 is indicative of the presence of non-cancerous or pre-cancerous breast condition in the subject.
  • the determining step comprises determining the expression level of PAX2 gene relative to the expression level of a control gene, determining the expression level of DEFB1 gene relative to the expression level of the same control gene; and determining the PAX2-to-DEFB1 expression ratio based on the expression levels of PAX2 and DEFB1.
  • the method further comprising determining an oestrogen receptor/progesterone receptor/human epidermal growth factor receptor 2 (ER/PR/HER2) status in cells obtained from the breast tissue with the breast condition.
  • ER/PR/HER2 oestrogen receptor/progesterone receptor/human epidermal growth factor receptor 2
  • kits for monitoring breast conditions comprises: one or more pairs of oligonucleotide primers for detecting PAX2 expression in a tissue sample, one or more pairs of oligonucleotide primers for detecting DEFB1 expression in the tissue sample, and instructions on how to determine the PAX2-to-DEFB1 expression ratio in a tissue sample using the primers.
  • the one or more pairs of oligonucleotide primers for detecting PAX2 expression comprising an oligonucleotide primer pair selected from the group consisting of SEQ ID NOS: 43 and 47, SEQ ID NOS: 44 and 48, and SEQ ID NOS: 45 and 49.
  • the one or more pairs of oligonucleotide primers for detecting DEFB1 expression comprising SEQ ID NOS: 35 and 37.
  • the kit further comprises one or more pairs of control oligonucleotide primers.
  • the one or more pairs of control oligonucleotide primers comprise oligonucleotide primers for detecting expression of ⁇ -actin expression.
  • the oligonucleotide primers for detecting expression of ⁇ -actin expression comprise SEQ ID NOS: 34 and 36.
  • the one or more pairs of control oligonucleotide primers comprise oligonucleotide primers for detecting expression of GAPDH expression.
  • the oligonucleotide primers for detecting expression of GAPDH expression comprise SEQ ID NOS: 42 and 46.
  • the kit further comprises one or more reagents for PCR reaction.
  • the kit further comprises one or more reagents for RNA extraction.
  • the kit for monitoring breast conditions comprises an oligonucleotide microarray having oligonucleotide probes for detecting PAX2 and DEFB1 expression and instructions on how to determine the PAX2-to-DEFB1 expression ratio in a tissue sample using the oligonucleotide microarray.
  • the kit further comprises reagents for extracting RNA from a tissue sample.
  • Another aspect of the invention relates to a method for determining a treatment regimen for a subject with a breast condition.
  • the method includes the step of determining the expression level of PAX2 gene relative to the expression level of a control gene in cells obtained from a breast tissue with the breast condition in said subject, and determining a treatment regimen for said subject based on the relative expression level of the PAX2 gene.
  • FIG. 1 shows quantitative RT-PCR (QRT-PCR) analysis of beta-defensin-1 (DEFB1) expression.
  • QRT-PCR quantitative RT-PCR
  • FIG. 1A shows DEFB1 relative expression levels compared in clinical samples from 6 patients that underwent radical prostatectomies.
  • FIG. 1B shows DEFB1 relative expression levels compared in benign and malignant prostatic clinical samples, hPrEC cells and in prostate cancer cell lines before and after DEFB1 induction.
  • FIG. 1C shows DEFB1 relative expression levels analyzed in benign tissue, malignant tissue and prostate intraepithelial neoplasia (PIN) in a single tissue section.
  • FIG. 1D shows DEFB1 expression in benign tissue, malignant tissue and PIN in one patient compared to the average DEFB1 expression level found in benign tissue.
  • FIG. 2 shows microscopic analysis of DEFB1 induced changes in membrane integrity and cell morphology.
  • Cell morphology of DU1445, PC3 and LNCaP was analyzed by phase contrast microscopy after 48 hours of DEFB1 induction.
  • Membrane ruffling is indicated by black arrows and apoptotic bodies are indicated white arrows.
  • FIG. 3 shows analysis of DEFB1 Cytotoxicity in Prostate Cancer Cells.
  • FIG. 4 shows induction of cell death in DU145 and PC3 cells by DEFB1.
  • DEFB1 expression was induced in prostate cancer cell lines DU145 (A) and PC3 (B) and then subjected to annexin V/FITC/propidium iodide staining and flow cytometric analysis. Cells positive for propidium iodide and annexin V were considered apoptotic. Times of induction are shown under each panel. Numbers next to the boxes for each time point represent the percentages of propidium iodide (PI) ⁇ annexin V+ cells (lower right quadrant), and PI+ annexin V+ cells (upper right quadrant). The data are from a single experiment that is representative of three separate experiments.
  • PI propidium iodide
  • FIG. 5 shows pan-caspase analysis following DEFB1 induction.
  • DU145 and PC3 cells were stained with FAM-VAD-FMK-labeled fluoromethyl ketone to detect caspase activity. Cells were visible under DIC for each condition. Confocal microscopic analysis revealed no caspase staining in control DU145 (B), PC3 cells (F) and LNCaP (J). Cells treated with PonA for 24 hours to induce DEFB1 revealed caspase activity in DU145 (D) and PC3 (H). No caspase activity was detected in LNCaP (L).
  • FIG. 6 shows silencing of paired box homeotic gene 2 (PAX2) protein expression following PAX2 siRNA Treatment.
  • FIG. 6A shows Western blot analysis of PC3 and DU145 cells transfected with PAX2 siRNA duplex at day zero (lane 1), day two (lane 2), and day four (lane 3).
  • FIG. 6B shows Western blot analysis of PC3 and DU145 cells transfected with PAX2 siRNA duplex at day zero (lane 1), day two (lane 2), day four (lane 3) and day 6 (lane 4).
  • PAX2 protein was undetectable as early as after four days of treatment (lane 3) in DU145 cells and after six days of treatment in PC3. Blots were stripped and re-probed for ⁇ -actin as an internal control.
  • FIG. 7 shows analysis of prostate cancer cells growth after treatment with PAX2 siRNA.
  • FIG. 8 shows analysis of cell death following siRNA silencing of PAX2.
  • FIG. 9 shows analysis of caspase activity.
  • DU145, PC3 and LNCaP cells were stained with carboxyfluorescein-labeled fluoromethyl ketone to detected caspase activity following treatment with PAX2 siRNA. Confocal microscopic analysis of untreated and treated cells show cells were visible with DIC. Analysis under fluorescence revealed no caspase staining in control DU145 (B), PC3 cells (F) and LNCaP cells (J). However, cell treated with PAX2 siRNA induced caspase activity in DU145 (D), PC3 (H) and LNCaP (L).
  • FIG. 10 shows analysis of apoptotic factors following PAX2 siRNA treatment. Changes in expression of pro-apoptotic factors were compared in untreated control cells and in cells treated for six days with PAX2 siRNA.
  • FIG. 10A shows Bcl-2-associated X protein (BAX) expression levels increased in DU145, PC3 and LNCaP.
  • FIG. 10B shows BH3 interacting domain death agonist (BID) expression increased in DU145 and LNCaP, but change in PC3.
  • FIG. 10C shows Bcl-2-associated death promoter (BAD) expression levels increased in all three cell lines.
  • BAX Bcl-2-associated X protein
  • FIG. 11 shows model of PAX2 binding to DNA recognition sequence.
  • the PAX2 transcriptional repressor binds to a CCTT1 (SEQ ID NO.: 1) recognition site immediately adjacent to the DEFB1 TATA box preventing transcription and DEFB1 protein expression. Inhibition of PAX2 protein expression allows normal DEFB1 expression.
  • FIG. 12 illustrates the DEFB1 reporter construct.
  • the DEFB1 promoter consisting of the first 160 bases upstream of the mRNA start site was PCR amplified from DU145 cell and ligated into the pGL3 luciferase reporter plasmid.
  • FIG. 13 shows inhibition of PAX2 results in DEFB1 Expression.
  • DU145, PC3, LNCaP and HPrEC were treated for 48 hours with PAX2 siRNA.
  • QRT-PCR analysis before treatment showed no DEFB1 expression in DU145, PC3 and LNCaP.
  • DEFB1 expression was restored following treatment in all lines.
  • FIG. 14 shows inhibition of PAX2 results in increased DEFB1 promoter activity.
  • PC3 promoter/pGL3 and DU145 promoter/pGL3 construct were generated and were transfected into PC3 and DU145 cells, respectively.
  • Promoter activity was compared before and after PAX2 inhibition by siRNA treatment.
  • DEFB1 promoter activity increased 2.65-fold in DU145 and 3.78 fold in PC3 following treatment.
  • FIG. 15 shows ChIP analysis of PAX2 binding to DEFB1 promoter. ChIP analysis was performed on DU145 and PC3 cells. Following immunoprecipitation with an anti-PAX2 antibody, PCR was performed to detect the DEFB1 promoter region containing the GTTCC (SEQ ID NO: 2) PAX2 recognition site. This demonstrates that the PAX2 transcriptional repressor is bound to the DEFB1 promoter in prostate cancer cell lines.
  • FIG. 16 shows predicted structure of the PrdPD and PrdHD with DNA.
  • the coordinates of the structures of the PrdPD bound to DNA (Xu et al., 1995) and the PrdHD bound to DNA (Wilson et al., 1995) were used to construct a model of the two domains as they bound to a PH0 site.
  • the individual binding sites are abutted next to each other with a specific orientation as indicated.
  • the RED domain is oriented based on the PrdPD crystal structure.
  • FIG. 17 shows comparison of consensus sequences of different paired domains.
  • a schematic representation of protein ⁇ DNA contacts described in the crystallographic analysis of the Prd-paired-domain ⁇ DNA complex is drawn. Empty boxes indicate a-helices, shaded boxes indicates b-sheets and a thick line indicate a b-turn. Contacting amino acids are shown by single-letter code. Only direct amino acid ⁇ base contacts are shown. Empty circles indicate major groove contacts while red arrows indicate minor groove contacts. This scheme is aligned to all known consensus sequences for paired-domain proteins (top strands only are shown). Vertical lines between consensus sequences indicate conserved base-pairs. Numbering of the positions is shown at the bottom of the Figure.
  • FIG. 18 shows targeting PAX2 as a chemopreventive strategy.
  • Aberrant PAX2 expression is an early event in the initiation and progression of cancer. Inhibition of PAX2 during dysplasia or other precancerous stage can be used for cancer prevention.
  • FIG. 19 shows effect of angiotensin II (Ang II) on PAX2 expression in DU145 Cells.
  • Ang II angiotensin II
  • DEFB1 protein levels was monitored following treatment.
  • PAX2 expression levels increased as early as 4 hours and persisted until 48 hours.
  • FIG. 20A shows effect of Losartan (Los) on PAX2 expression in DU145.
  • DU145 cells were treated with the angiotensin II type 1 receptor (ATR1) blocker Losartan.
  • ATR1 angiotensin II type 1 receptor
  • FIG. 20B shows effect of an angiotensin II type 2 receptor (ATR2) blocker on PAX2 Expression in DU145.
  • ATR2 angiotensin II type 2 receptor
  • FIG. 21 shows Los blocks AngII effect on PAX2 expression in DU145.
  • Treatment of DU145 cells with 5 ⁇ M of AngII for 72 hours resulted in a 2-fold increase in PAX2 expression.
  • treatment with 10 ⁇ M for 72 hours resulted in more than a 3-fold increase in expression.
  • Treatment of cells with 5 ⁇ M of Losartan suppressed proliferation by 50%.
  • treatment with Losartan for 30 min prior to treatment with AngII blocked the effect of AngII on proliferation.
  • FIG. 22 shows AngII increases DU145 cell proliferation.
  • Treatment of DU145 cells with 5 ⁇ M of AngII for 72 hours resulted in a 2-fold increase in proliferation.
  • treatment with 10 ⁇ M for 72 hours resulted in more than a 3-fold increase in proliferation.
  • FIG. 23 shows effect of Los and MAP Kinase inhibitors on PAX2 expression in DU145 cells.
  • FIG. 23A shows treatment of DU145 cells with Losartan suppresses phosphor-ERK 1/2 and PAX2 expression;
  • FIG. 23B shows MEK kinase inhibitors and AICAR suppresses PAX2 protein expression;
  • FIG. 23C shows MEK kinase inhibitors and Losartan suppresses phospho-STAT3 protein expression.
  • FIG. 24 shows effect of Los and MEK kinase inhibitors on PAX2 activation in DU145 cells.
  • FIG. 24A shows treatment of DU145 cells with inhibitors of AT1R signaling resulted in a decrease in phosphor-PAX2 protein levels which is the active form of PAX2.
  • FIG. 24B shows inhibition of AT1R signaling with Los decreased phopho-JNK levels. However, AngII increased phosphor-JNK protein levels.
  • FIG. 25 shows AngII increases PAX2 and decreases DEFB1 expression in hPrEC cells.
  • AngII increases PAX2 and decreases DEFB1 expression in hPrEC cells.
  • cells were treated for 72 and 96 hours and PAX2 and DEFB1 expression was examined by QRT-PCR.
  • AngII treatment resulted in dramatic increases in PAX2 to levels similar to PC3 prostate cancer cells.
  • DEFB1 expression was reduced significantly after AngII treatment.
  • FIG. 26 shows schematic of AngII signaling and PAX2 prostate cancer.
  • PAX2 expression in prostate cancer cells is regulated by the AT1R signaling pathway.
  • the MEK kinase signaling cascade leads to increased PAX2 expression.
  • the AT1R and AngII upregulates PAX2 activation via INK.
  • FIG. 27 shows schematic of blocking PAX2 expression as a therapy for prostate cancer.
  • FIG. 27A shows PAX2 expression is regulated by the AT1R signaling pathway, Inhibition of PAX2 expression results in the re-expression of DEFB1 and cancer cell death.
  • FIG. 27B shows compounds which block the AT1R, downstream kinases or directly suppresses PAX2 offer a novel approach to treating prostate cancer.
  • FIG. 28 shows comparison of DEFB1 and PAX2 expression with Gleason Score.
  • DEFB1 relative expression levels were compared in benign clinical samples from 6 patients that underwent radical prostatectomies.
  • Gleason score inversely correlated with DEFB1 expression levels in adjacent benign prostate tissue.
  • Patients with relative DEFB1 expression levels higher than 0.005 had Gleason sores of 6.
  • those with expression levels less than 0.005 had Gleason scores of 7.
  • FIG. 29 shows PAX2-DEFB1 ratio as a predictive factor for prostate cancer development.
  • QRT-PCR was performed on laser capture microdissection (LCM) prostate tissue sections to determine relative DEFB1 and PAX2 expression levels.
  • DEFB1 expression levels decreased from Normal to PIN to cancer.
  • PAX2 expression increased from normal to PI to cancer.
  • patient #1457 with Gleason score 6 cancer had more DEFB1 in normal tissue and PIN compared to patient #1569 with Gleason score 7 cancer.
  • patient #1569 had higher PAX2 levels in cancerous regions compared to patient #1457.
  • FIG. 30 shows the Donald Predictive Factor (DPF) is based on the relative PAX2-DEFB1 expression ratio.
  • DPF Donald Predictive Factor
  • FIG. 31 shows analysis of hBD-1 expression in human prostate tissue. hBD-1 relative expression levels were compared in normal clinical samples from patients that underwent radical prostatectomies. The dashed line serves as a point of reference to compare values obtained between gross and LCM-derived specimen, and corresponding Gleason scores are indicated above each bar.
  • FIG. 31A shows hBD-1 expression levels compared in tissues obtained by gross dissection.
  • FIG. 31B shows hBD-1 expression levels compared in tissue obtained by Laser Capture Microdissection.
  • FIG. 32 shows analysis of hBD-1 expression in prostate cell lines.
  • FIG. 32A shows hBD-1 expression levels compared relative to hPrEC cells in prostate cancer cell lines before and after hBD-1 induction.
  • An asterisk represents statistically higher expression levels compared to hPrEC.
  • Double asterisks represent statistically significant levels of expression compared to the cell line before hBD-1 induction (Student's t-test, p ⁇ 0.05).
  • FIG. 32B shows ectopic hBD-1 expression verified in the prostate cancer cell line DU145 by immunocytochemistry.
  • hPrEC cells were stained for hBD-1 as appositive control (a: DIC and b: fluorescence).
  • FIG. 33 shows analysis of hBD-1 cytotoxicity in prostate cancer cells.
  • the prostate cell lines DU145, PC3, PC3/AR+ and LNCaP were treated with Pon A to induce hBD-1 expression for 1-3 days after which MTT assay was performed to determine cell viability.
  • Each bar represents the mean ⁇ S.E.M. of three independent experiments performed in triplicate.
  • FIG. 34 shows QRT-PCR analysis of hBD-1 and cMYC expression in LCM human prostate tissue sections of normal, PIN and tumor. Expression for each gene is presented as expression ratios compared to ⁇ -actin.
  • FIG. 35A shows comparison of hBD-1 expression levels in normal, PIN and tumor sections.
  • FIG. 35B shows comparison of cMYC expression level in normal, PIN and tumor sections.
  • FIG. 35 shows QRT-PCR analysis of hBD1 expression following PAX2 knockdown with siRNA.
  • hBD-1 expression levels are presented as expression ratios compared to ⁇ -actin.
  • An asterisk represents statistically higher expression levels compared to the cell line before PAX2 siRNA treatment (Student's t-test, p ⁇ 0.05).
  • FIG. 36 shows silencing of PAX2 protein expression following PAX2 siRNA treatment.
  • FIG. 37A shows PAX2 expression examined by Western blot analysis in HPrEC prostate primary cells (lane 1) and in DU145 (lane 2), PC3 (lane 3) and LNCaP (lane 4) prostate cancer cells. Blots were stripped and re-probed for -actin as an internal control to ensure equal loading.
  • FIG. 37B shows Western blot analysis of DU145, PC3 and LNCaP all confirmed knockdown of PAX2 expression following transfection with PAX2 siRNA duplex. Again, blots were stripped and re-probed for ⁇ -actin as an internal control.
  • FIG. 37 shows analysis of prostate cancer cells growth after treatment with PAX2 siRNA.
  • FIG. 38 shows analysis of cell death following siRNA silencing of PAX2.
  • FIG. 39 shows analysis of caspase activity.
  • FIG. 40 shows analysis of apoptotic factors following PAX2 siRNA treatment. Changes in expression of pro-apoptotic factors were compared in untreated control cells and in cells treated for 6 days with PAX2 siRNA.
  • FIG. 41A shows BAD expression increased in DU145, PC3 and LNCaP following PAX2 knockdown.
  • FIG. 41B shows BID expression levels increased in LNCaP and DU145, but not in PC3 cells.
  • the method relates to a method for monitoring cancer development.
  • the method relates to monitoring pre-cancerous conditions, such as intraepithelial neoplasia, and cancerous conditions in the prostate or breast of a subject.
  • the method comprises determining a Paired Box 2 gene-to-beta defensin-1 gene (PAX2-to-DEFB1) expression ratio in cells obtained from the prostate or breast of the subject, wherein the PAX2-to-DEFB1 expression ratio is correlated with prostate or breast conditions.
  • the gene expression ratio may be determined at the mRNA level (e.g., by RT-PCR or oligonucleotide array) or at the protein level (e.g., by Western blot or antibody a ray).
  • the PAX2-to-DEFB1 expression ratio is determined at the mRNA level and is referred to as the “Donald Predictive Factor” or “DPF” in the specification.
  • the PAX2-to-DEFB1 expression ratio (determined at the RNA level) in prostate is used for distinguishing among normal pre-cancerous and cancerous prostate conditions in the subject.
  • a PAX2-to-DEFB1 ratio of less than 40:1 is indicative of a normal prostate condition
  • a PAX2-to-DEFB1 ratio of at least 40:1 to less than 100:1 is indicative of prostate intraepithelial neoplasia (PIN)
  • PIN prostate intraepithelial neoplasia
  • PAX2-to-DEFB1 ratio of at least 100:1 is indicative of prostate cancer.
  • the method comprises detecting in cells from the prostate of the subject levels of PAX2 and beta defensin-1 (DEFB1), wherein the ratio of PAX2 to DEFB1 is at least 100:1.
  • DEFB1 beta defensin-1
  • the method comprises detecting in cells from the prostate of the subject levels of PAX2 and beta DEFB1, wherein the ratio of PAX2 to DEFB1 is at least 40:1 and less than 100:1.
  • the PAX2-to-DEFB1 expression ratio (at the RNA level) in breast is used for distinguishing among non-cancerous (benign and/or pre-cancerous) and cancerous breast conditions in the subject.
  • a PAX2-to-DEFB1 ratio less than 100:1 is indicative of non-cancerous (normal) and/or pre-cancerous (mammary intraepithelial neoplasia (MIN)), and a PAX2-to-DEFB1 ratio of at least 100:1 is indicative of breast cancer.
  • a method for diagnosing breast cancer in a subject comprises detecting in cells from the breast of the subject levels of PAX2 and DEFB1, wherein the ratio of PAX2 to DEFB1 of at least 100:1 is indicative of breast cancer in the subject. Also provided is a method of diagnosing non-cancerous breast conditions (normal and/or MIN) in a subject. The method comprises detecting in cells from the breast of the subject levels of PAX2 and DEFB1, wherein the ratio of PAX2 to DEFB1 of less than 100:1 is indicative of non-cancerous breast conditions in the subject.
  • the method further comprising determining an oestrogen receptor/progesterone receptor (ER/PR) status in cells obtained from the breast tissue with the breast condition.
  • ER/PR oestrogen receptor/progesterone receptor
  • the ER/PR status of the breast tissue may be used, in combination with the PAX2-to-DEFB 1 ratio in the same tissue, for determining the breast conditions in the subject.
  • mammary intraepithelial neoplasia includes lobular intraepithelial neoplasia and ductal intraepithelial neoplasia.
  • the monitoring and diagnosing methods of the present invention provide clinicians with a prognosticator for initiated or pre-cancerous tissue.
  • Candidates for this test include patients at high risk (based on age, race) for cancer.
  • a positive or negative PAX2 test can then be followed by additional screening with biomarker to determine cancer site.
  • these patients can be candidates for treatment with PAX2/DEFB1 modulators.
  • this test can be used on patients (i.e., those with triple negative breast cancer) as a measure of the effectiveness of their cancer therapy, to determine treatment course, or to monitor cancer recurrence.
  • Prostate cancer screening currently consists of a rectal examination and measurement of prostate specific antigen (PSA) levels. These methods lack specificity as digital rectal examination has considerable inter-examiner variability and PSA levels may be elevated in benign prostatic hyperplasia (BPH), prostatic inflammation and other conditions.
  • PSA prostate specific antigen
  • Prostate cancers can be scored using the Gleason system (Gleason, et al. 1966). This uses tissue architecture rather than cytological features. A grade of 1 to 5 (well to poorly differentiated) is used, and the combined score of the most frequent and more severe areas of the lesion are combined. Gleason scores provide prognostic information that may be valuable in addition to the assessment of the stage of the tumor (staging). Gleason scores of 2 to 4 and 8 to 10 have good predictive value, but about three quarters of tumors have intermediate values.
  • TNM Two principal systems are used for staging prostate cancer: TNM and the Jewett system (Benson & Olsson, et al. 1989). Staging takes in to account any metastatic spread of the tumor and is difficult, because it is difficult to assess either local lymph node involvement or local invasion. Tumor size is also difficult to measure as tumor tissue cannot be distinguished macroscopically from normal prostate tissue, and because the prostate gland lacks a distinct capsule and is surrounded by a layer of fibrous fatty tissue.
  • T prostate tumor's stage
  • T1 the cancer is microscopic, unilateral and non palpable.
  • the doctor can't feel the tumor or see it with imaging such as transrectal ultrasound.
  • Treatment for BPH may have disclosed the disease, or it was confirmed through the use of a needle biopsy done because of an elevated PSA.
  • T2 the doctor can feel the cancer with a DRE. It appears the disease is confined to the prostate gland on one or both sides of the gland.
  • T3 the cancer has advanced to tissue immediately outside the gland.
  • T4 the cancer has spread to other parts of the body.
  • the commonly used screening methods for breast cancer include self and clinical breast exams, x-ray mammography, and breast Magnetic Resonance Imaging (MRI).
  • MRI breast Magnetic Resonance Imaging
  • the most recent technology for breast cancer screening is ultrasound computed tomography, which uses sound waves to create a three-dimensional image and detect breast cancer without the use of dangerous radiation used in x-ray mammography.
  • Genetic testing may also be used. Genetic testing for breast cancer typically involves testing for mutations in the BRCA genes. It is not a generally recommended technique except for those at elevated risk for breast cancer.
  • the principal manner of identifying breast cancer is through detection of the presence of dense tumorous tissue. This may be accomplished to varying degrees of effectiveness by direct examination of the outside of the breast, or through mammography or other X-ray imaging methods (Jatoi, 1999, Am. J. Surg. 177:518-524). The latter approach is not without considerable cost, however. Every time a mammogram is taken, the patient incurs a small risk of having a breast tumor induced by the ionizing properties of the radiation used during the test.
  • PAX genes are a family of nine developmental control genes coding for nuclear transcription factors. They play an important role in embryogenesis and are expressed in a very ordered temporal and spatial pattern. They all contain a “paired box” region of 384 base pairs encoding a DNA binding domain which is highly conserved throughout evolution (Stuart, E T, et al. 1994). The influence of Pax genes on developmental processes has been demonstrated by the numerous natural mouse and human syndromes that can be attributed directly to even a heterozygous insufficiency in a Pax gene. A PAX2 sequence is given in Dressler, et al. 1990.
  • SEQ ID NOS: 58-69 SEQ ID NO:58, amino acid sequence encoded by exon 1 of the human PAX2 gene; SEQ ED NO:59, human PAX2 gene promoter and exon 1; SEQ ID NO:60, amino acid sequence of the human PAX2; SEQ ID NO:61, human PAX2 gene; SEQ ID NO:62, amino acid sequence of the human PAX2 gene variant b; SEQ ID NO:63, human PAX2 gene variant b; SEQ ID NO:64, amino acid sequence of the human PAX2 gene variant c; SEQ ID NO:65, human PAX2 gene variant c; SEQ ID NO:66, amino acid sequence of the human PAX2 gene variant d; SEQ ID NO:67, human PAX2 gene variant d, SEQ ID NO:68, amino acid sequence of the human PAX2 gene variant e; SEQ ID NO:
  • PAX2-expressing cancers PAX2 Expressing Estimated New Estimated Estimated New Estimated Cancers Cases in US Deaths in US Cases Global Deaths Global Prostate 234,460 27,350 679,023 221,002 Breast 214,600 41,430 1,151,298 410,712 Ovarian 20,180 15,310 204,500 124,860 Renal 38,890 12,840 208,479 101,895 Brain 12,820 18,820 189,485 141,650 Cervical 9,710 3,700 493,243 273,505 Bladder 61,420 13,060 356,556 145,009 Leukemia 35,020 22,280 300,522 222,506 Kaposi Sarcoma Data Not Data Not Data Not Data Not Available Available Available Available TOTAL(approx.) 627,100 154,790 3,583,106 1,641,139
  • Beta-defensins are cationic peptides with broad-spectrum antimicrobial activity that are products of epithelia and leukocytes. These two exon, single gene products are expressed at epithelial surfaces and secreted at sites including the skin, cornea, tongue, gingiva, salivary glands, esophagus, intestine, kidney, urogenital tract, and the respiratory epithelium.
  • beta-defensin genes of epithelial origin have been identified and characterized in humans: DEFB1 (Bensch et al., 1995), DEFB 2 (Harder et al., 1997), DEFB3 (Harder et al., 2001; Jia et al., 2001), DEFB4, and HE2/EP2.
  • each beta-defensin gene product is characterized by small size, a six cysteine motif, high cationic charge and extraordinar diversity beyond these features.
  • the most characteristic feature of defensin proteins is their six-cysteine motif that forms a network of three disulfide bonds.
  • the three disulfide bonds in the beta-defensin proteins are between C1-C5, C2-C4 and C3-C6.
  • the most common spacing between adjacent cysteine residues is 6, 4, 9, 6, 0.
  • the spacing between the cysteines in the beta-defensin proteins can vary by one or two amino acids except for C5 and C6, located nearest the carboxy terminus. In all known vertebrate beta-defensin genes, these two cysteine residues are adjacent to each other.
  • beta-defensin proteins A second feature of the beta-defensin proteins is their small size.
  • Each beta-defensin gene encodes a preproprotein that ranges in size from 59 to 80 amino acids with an average size of 65 amino acids. This gene product is then cleaved by an unknown mechanism to create the mature peptide that ranges in size from 36 to 47 amino acids with an average size of 45 amino acids. The exceptions to these ranges are the EP2/HE2 gene products that contain the beta-defensin motif and are expressed in the epididymis.
  • a third feature of beta-defensin proteins is the high concentration of cationic residues.
  • the number of positively charged residues (arginine, lysine, histidine) in the mature peptide ranges from 6 to 14 with an average of 9.
  • beta-defensin gene products are their diverse primary structure but apparent conservation of tertiary structure. Beyond the six cysteines, no single amino acid at a given position is conserved in all known members of this protein family. However, there are positions that are conserved that appear to be important for secondary and tertiary structures and function.
  • the structural core is a triple-stranded, antiparallel beta-sheet, as exemplified for the proteins encoded by BNBD-12 and DEFB2.
  • the three beta-strands are connected by a beta-turn, and an alpha-hairpin loop, and the second beta-strand also contains a beta-bulge.
  • the BBD-2 protein encoded by the DEFB2 gene exhibited an alpha-helical segment near the N-terminus not previously ascribed to solution structures of alpha-defensins or to the beta-defensin BNBD-12.
  • the amino acids whose side chains are directed toward the surface of the protein are less conserved between beta defensin proteins while the amino acid residues in the three beta-strands of the core beta-sheet are more highly conserved.
  • Beta-defensin peptides are produced as pre-pro-peptides and then cleaved to release a C-terminal active peptide fragment; however the pathways for the intracellular processing, storage and release of the human beta-defensin peptides in airway epithelia are unknown.
  • Levels of PAX2 and DEFB1 expression in a tissue can be measured any method known in the art.
  • the levels of PAX2 and DEFB1 expression in a target tissue are determined by determining the levels of PAX2 and DEFB1 in a cell or cells obtained directly from the target tissue, such as a biopsy sample.
  • the levels of PAX2 and DEFB1 expression in a target tissue are determined indirectly by determining the levels of PAX2 and DEFB1 in certain body fluids such as blood or plasma.
  • levels of PAX2 and DEFB1 expression in the prostate or breast of the subject can be measured using a cell sample from the prostate or breast.
  • Cell samples include biopsy samples of the prostate or breast and blood sample.
  • Biopsy is a procedure in which small tissue samples are removed from a target organ for further analysis. Prostate biopsy is typically performed when the scores from a PSA blood test rise to a level that is associated with the possible presence of prostate cancer. Similarly, breast biopsy is typically performed in patients with breast lumps or suspicious mammograms.
  • RNA levels can be measured, for example, with DNA arrays, RT-PCR and Northern Blotting.
  • the protein levels may be measured with immunoassays and enzyme assays.
  • the PAX2-to-DEFB1 expression ratio is determined by determining the expression level of PAX2 gene relative to the expression level of a control gene, determining the expression level of DEFB1 gene relative to the expression level of the same control gene, and calculating the PAX2-to-DEFB1 expression ratio based on the expression levels of PAX2 and DEFB1.
  • the control gene is the glyceraldehyde 3-phosphate dehydrogenase (GAPDH) gene.
  • GPDH glyceraldehyde 3-phosphate dehydrogenase
  • An oligonucleotide microarray consists of an arrayed series of a plurality of microscopic spots of oligonucleotides, called features, each containing a small amount (typically in the range of picomoles) of a specific oligonucleotide sequence.
  • the specific oligonucleotide sequence can be a short section of a gene or other oligonucleotide element that are used as probes to hybridize a cDNA or cRNA sample under high-stringency conditions.
  • Probe-target hybridization is usually detected and quantified by fluorescence-based detection of fluorophore-labeled targets to determine relative abundance of nucleic acid sequences in the target.
  • the probes are typically attached to a solid surface by a covalent bond to a chemical matrix (via epoxy-silane, amino-silane, lysine, polyacrylamide or others).
  • the solid surface can be glass or a silicon chip or microscopic beads.
  • Oligonucleotide arrays are different from other types of microarray only in that they either measure nucleotides or use oligonucleotide as part of its detection system.
  • nucleic acid of interest is purified from the target tissue or cells.
  • the nucleotide can be all RNA for expression profiling, DNA for comparative hybridization, or DNA/RNA bound to a particular protein which is immunoprecipitated (ChIP-on-chip) for epigenetic or regulation studies.
  • total RNA is isolated (total as it is nuclear and cytoplasmic) by guanidinium thiocyanate-phenol-chloroform extraction (e.g. Trizol).
  • the purified RNA may be analyzed for quality (e.g., by capillary electrophoresis) and quantity (e.g., by using a nanodrop spectrometer.
  • the total RNA is RNA is reverse transcribed into DNA with either polyT primers or random primers.
  • the DNA products may be optionally amplified by PCR.
  • a label is added to the amplification product either in the RT step or in an additional step after amplification if present.
  • the label can be a fluorescent label or radioactive labels.
  • the labeled DNA products are then hybridized to the microarray.
  • the microarray is then washed and scanned.
  • the expression level of the gene of interest is determined based on the hybridization result using method well known in the art.
  • Immunoassays in their most simple and direct sense, are binding assays involving binding between antibodies and antigen. Many types and formats of immunoassays are known and all are suitable for detecting the disclosed biomarkers. Examples of immunoassays are enzyme linked immunosorbent assays (ELISAs), radioimmunoassays (RIA), radioimmune precipitation assays (RIPA), immunobead capture assays, Western blotting, dot blotting, gel-shift assays, Flow cytometry, protein arrays, multiplexed bead arrays, magnetic capture, in vivo imaging, fluorescence resonance energy transfer (FRET), and fluorescence recovery/localization after photobleaching (FRAP/FLAP).
  • ELISAs enzyme linked immunosorbent assays
  • RIA radioimmunoassays
  • RIPA radioimmune precipitation assays
  • immunobead capture assays Western blotting, dot blotting, gel-shift assays
  • immunoassays involve contacting a sample suspected of containing a molecule of interest (such as the disclosed biomarkers) with an antibody to the molecule of interest or contacting an antibody to a molecule of interest (such as antibodies to the disclosed biomarkers) with a molecule that can be bound by the antibody, as the case may be, under conditions effective to allow the formation of immunocomplexes.
  • the sample-antibody composition such as a tissue section, ELISA plate, dot blot or Western blot, can then be washed to remove any non-specifically bound antibody species, allowing only those antibodies specifically bound within the primary immune complexes to be detected.
  • Radioimmune Precipitation Assay is a sensitive assay using radiolabeled antigens to detect specific antibodies in serum. The antigens are allowed to react with the serum and then precipitated using a special reagent such as, for example, protein A sepharose beads. The bound radiolabeled immunoprecipitate is then commonly analyzed by gel electrophoresis. Radioimmunoprecipitation assay (RIPA) is often used as a confirmatory test for diagnosing the presence of HIV antibodies.
  • RIPA is also referred to in the art as Farr Assay, Precipitin Assay, Radioimmune Precipitin Assay; Radioimmunoprecipitation Analysis; Radioimmunoprecipitation Analysis, and Radioimmuinioprecipitation Analysis.
  • immunoassays wherein the protein or antibody specific for the protein is bound to a solid support (e.g., tube, well, bead, or cell) to capture the antibody or protein of interest respectively, from a sample, combined with a method of detecting the protein or antibody specific for the protein on the support.
  • a solid support e.g., tube, well, bead, or cell
  • RIA Radioimmunoassay
  • ELISA Enzyme-Linked Immunosorbent Assay
  • Flow cytometry protein array, multiplexed bead assay, and magnetic capture.
  • Protein arrays are solid-phase ligand binding assay systems using immobilized proteins on surfaces which include glass, membranes, microtiter wells, mass spectrometer plates, and beads or other particles.
  • the assays are highly parallel (multiplexed) and often miniaturized (microarrays, protein chips). Their advantages include being rapid and autonmatable, capable of high sensitivity, economical on reagents, and giving an abundance of data for a single experiment. Bioinformatics support is important; the data handling demands sophisticated software and data comparison analysis. However, the software can be adapted from that used for DNA arrays, as can much of the hardware and detection systems.
  • Capture arrays form the basis of diagnostic chips and arrays for expression profiling. They employ high affinity capture reagents, such as conventional antibodies, single domains, engineered scaffolds, peptides or nucleic acid aptamers, to bind and detect specific target ligands in high throughput manner.
  • Antibody arrays are available commercially.
  • Fab and scFv fragments single V-domains from camelids or engineered human equivalents (Domantis, Waltham, Mass.) may also be useful in arrays.
  • Nonprotein capture molecules notably the single-stranded nucleic acid aptamers which bind protein ligands with high specificity and affinity, are also used in arrays (SomaLogic, Boulder, Colo.).
  • Aptamers are selected from libraries of oligonucleotides by the SelexTM procedure and their interaction with protein can be enhanced by covalent attachment, through incorporation of brominated deoxyuridine and UV-activated crosslinking (photoaptamers). Photocrosslinkinig to ligand reduces the crossreactivity of aptamers due to the specific steric requirements.
  • Aptamers have the advantages of ease of production by automated oligonucleotide synthesis and the stability and robustness of DNA; on photoaptamer arrays, universal fluorescent protein stains can be used to detect binding.
  • An alternative to an array of capture molecules is one made through ‘molecular imprinting’ technology, in which peptides (e.g., from the C-terminal regions of proteins) are used as templates to generate structurally complementary, sequence-specific cavities in a polymerizable matrix; the cavities can then specifically capture (denatured) proteins that have the appropriate primary amino acid sequence (ProteinPrintTM, Aspira Biosystems, Burlingame, Calif.).
  • ProteinChip® array (Ciphergen, Fremont, Calif.), in which solid phase chromatographic surfaces bind proteins with similar characteristics of charge or hydrophobicity from mixtures such as plasma or tumor extracts, and SELDI-TOF mass spectrometry is used to detection the retained proteins.
  • antibodies is used herein in a broad sense and includes both polyclonal and monoclonal antibodies.
  • immunoglobulin molecules also included in the term “antibodies” are fragments or polymers of those immunoglobulin molecules, and human or humanized versions of immunoglobulin molecules or fragments thereof, as long as they are chosen for their ability to interact with, for example, PAX2 or DEFB1, such that PAX2 is inhibited from interacting with DEFB1.
  • Antibodies that bind the disclosed regions of PAX2 or DEFB1 involved in the interaction between PAX2 and DEFB1 are also disclosed.
  • the antibodies can be tested for their desired activity using the in vitro assays described herein, or by analogous methods, after which their in vivo therapeutic and/or prophylactic activities are tested according to known clinical testing methods.
  • the monoclonal antibodies herein specifically include “chimeric” antibodies in which a portion of the heavy and/or light chain is identical with or homologous to corresponding sequences in antibodies derived from a particular species or belonging to a particular antibody class or subclass, while the remainder of the chain(s) is identical with or homologous to corresponding sequences in antibodies derived from another species or belonging to another antibody class or subclass, as well as fragments of such antibodies, as long as they exhibit the desired antagonistic activity (See, U.S. Pat. No. 4,816,567 and Morrison et al., Proc. Natl. Acad. Sci. USA, 81:6851-6855 (1984)).
  • antibody can also refer to a human antibody and/or a humanized antibody.
  • Many non-human antibodies e.g., those derived from mice, rats, or rabbits
  • are naturally antigenic in humans and thus can give rise to undesirable immune responses when administered to humans. Therefore, the use of human or humanized antibodies in the methods serves to lessen the chance that an antibody administered to a human will evoke an undesirable immune response.
  • Methods for humanizing nonhuman antibodies are well known in the art.
  • the PAX2 and/or DEFB1 expression profiles are used for determine pharmacogenomics of breast cancer.
  • Pharmacogenomics refers to the relationship between an individual's genotype and that individual's response to a foreign compound or drug. Differences in metabolism of therapeutics can lead to severe toxicity or therapeutic failure by altering the relation between dose and blood concentration of the pharmacologically active drug.
  • a physician or clinician may consider applying knowledge obtained in relevant pharmacogenomics studies in determining whether to administer an anti-cancer drug, as well as tailoring the dosage and/or therapeutic regimen of treatment with the anti-cancer drug.
  • Pharmacogenomics deals with clinically significant hereditary variations in the response to drugs due to altered drug disposition and abnormal action in affected persons.
  • two types of pharmacogenetic conditions can be differentiated. Genetic conditions transmitted as a single factor altering the way drugs act on the body (altered drug action) or genetic conditions transmitted as single factors altering the way the body acts on drugs (altered drug metabolism). These pharmacogenetic conditions can occur either as rare genetic defects or as naturally-occurring polymorphisms.
  • G6PD glucose-6-phosphate dehydrogenase deficiency
  • oxidant drugs anti-malarials, sulfonamides, analgesics, nitrofurans
  • a genome-wide association relies primarily on a high-resolution map of the human genome consisting of already known gene-related sites (e.g., a “bi-allelic” gene marker map which consists of 60,000-100,000 polymorphic or variable sites on the human genome, each of which has two variants).
  • a high-resolution genetic map can be compared to a map of the genome of each of a statistically substantial number of subjects taking part in a Phase II/III drug trial to identify genes associated with a particular observed drug response or side effect.
  • such a high resolution map can be generated from a combination of some ten-million known single nucleotide polymorphisms (SNPs) in the human genome.
  • SNPs single nucleotide polymorphisms
  • an “SNP” is a common alteration that occurs in a single nucleotide base in a stretch of DNA. For example, an SNP may occur once per every 1,000 bases of DNA. An SNP may be involved in a disease process. However, the vast majority of SNPs may not be disease associated. Given a genetic map based on the occurrence of such SNPs, individuals can be grouped into genetic categories depending on a particular pattern of SNPs in their individual genome.
  • treatment regimens can be tailored to groups of genetically similar individuals, taking into account traits that may be common among such genetically similar individuals.
  • mapping of the PAX2 and/or DEFB1 to SNP maps of breast patients may allow easier identification of these genes according to the genetic methods described herein.
  • a method termed the “candidate gene approach,” can be utilized to identify genes that predict drug response. According to this method, if a gene that encodes a drug target is known, all common variants of that gene can be fairly easily identified in the population and it can be determined if having one version of the gene versus another is associated with a particular drug response.
  • the activity of drug metabolizing enzymes is a major determinant of both the intensity and duration of drug action.
  • drug metabolizing enzymes e.g., N-acetyltransferase 2 (NAT 2) and cytochrome P450 enzymes CYF2D6 and CYPZC19
  • NAT 2 N-acetyltransferase 2
  • CYF2D6 and CYPZC19 cytochrome P450 enzymes
  • the gene coding for CYP2D6 is highly polymorphic and several mutations have been identified in poor metabolizers, which all lead to the absence of functional CYP2D6. Poor metabolizers of CYP2D6 and CYP2C19 quite frequently experience exaggerated drug response and side effects when they receive standard doses. If a metabolite is the active therapeutic moiety, poor metabolizers show no therapeutic response, as demonstrated for the analgesic effect of codeine mediated by its CYP2D6-formed metabolite morphine. The other extreme are the so called ultra-rapid metabolizers who do not respond to standard doses, Recently, the molecular basis of ultra-rapid metabolism has been identified to be due to CYP2D6 gene amplification.
  • gene expression profiling can be utilized to identify genes that predict drug response. For example, the gene expression of an animal dosed with a drug can give an indication whether gene pathways related to toxicity have been turned on.
  • Information generated from more than one of the above pharmacogenomics approaches can be used to determine appropriate dosage and treatment regimens for prophylactic or therapeutic treatment an individual. This knowledge, when applied to dosing or drug selection, can avoid adverse reactions or therapeutic failure and thus enhance therapeutic or prophylactic efficiency when treating a subject with a breast condition.
  • the PAX2 and/or DEFB1 expression profiles, as well as the ER/PR status, in a subject are used to determine the appropriate treatment regimens for an individual with a breast condition.
  • the PAX2 expression level (typically determine in reference to a control gene as actin gene or GAPDH gene) is used in patients with triple negative breast cancer (i.e., oestrogen receptor (ER) negative, progesterone receptor (PR) negative, human epidermal growth factor receptor 2 (HER2) negative) to measure of the effectiveness of cancer therapy, to determine treatment course, or to monitor cancer recurrence.
  • triple negative breast cancer i.e., oestrogen receptor (ER) negative, progesterone receptor (PR) negative, human epidermal growth factor receptor 2 (HER2) negative
  • ER oestrogen receptor
  • PR progesterone receptor
  • HER2 human epidermal growth factor receptor 2
  • kits for monitoring breast conditions comprises: one or more pairs of oligonucleotide primers for detecting PAX2 expression in a tissue sample, one or more pairs of oligonucleotide primers for detecting DEFB1 expression in the tissue sample, and instructions on how to determine the PAX2-to-DEFB1 expression ratio in a tissue sample using the primers.
  • the one or more pairs of oligonucleotide primers for detecting PAX2 expression comprising an oligonucleotide primer pair selected from the group consisting of SEQ ID NOS: 43 and 47, SEQ ID NOS: 44 and 48, and SEQ ID NOS: 45 and 49.
  • the one or more pairs of oligonucleotide primers for detecting DEFB1 expression comprising SEQ ID NOS: 35 and 37.
  • the kit further comprises one or more pairs of control oligonucleotide primers.
  • the one or more pairs of control oligonucleotide primers comprise oligonucleotide primers for detecting expression of ⁇ -actin expression.
  • the oligonucleotide primers for detecting expression of ⁇ -actin expression comprise SEQ ID NOS: 34 and 36.
  • the one or more pairs of control oligonucleotide primers comprise oligonucleotide primers for detecting expression of GAPDH expression.
  • the oligonucleotide primers for detecting expression of GAPDH expression comprise SEQ ID NOS: 42 and 46.
  • the kit further comprises one or more reagents for PCR reaction.
  • the kit further comprises one or more reagents for RNA extraction.
  • the kit for monitoring breast conditions comprises an oligonucleotide microarray having oligonucleotide probes for detecting PAX2 and DEFB1 expression and instructions on how to determine the PAX2-to-DEFB1 expression ratio in a tissue sample using the oligonucleotide microarray.
  • the kit further comprises reagents for extracting RNA from a tissue sample.
  • Human Beta Defensin-1 is Cytotoxic to Late-Stage Prostate Cancer and Plays a Role in Prostate Cancer Tumor Immunity
  • DEFB1 was cloned into an inducible expression system to examine what effect it had on normal prostate epithelial cells, as well as androgen receptor positive (AR+) and androgen receptor negative (AR ⁇ ) prostate cancer cell lines. Induction of DEFB1 expression resulted in a decrease in cellular growth in AR ⁇ cells DU145 and PC3, but had no effect on the growth of the AR+prostate cancer cells LNCaP. DEFB1 also caused rapid induction of caspase-mediated apoptosis. Data presented here are the first to provide evidence of its role in innate tumor immunity and indicate that its loss contributes to tumor progression in prostate cancer.
  • the cell lines DU145 were cultured in DMEM medium, PC3 were grown in F12 medium, and LNCaP were grown in RPMI medium (Life Technologies, Inc., Grand Island, N.Y.). Growth media for all three lines was supplemented with 10% (v/v) fetal bovine serum (Life Technologies).
  • the hPrEC cells were cultured in prostate epithelium basal media (Cambrex Bio Science, Inc., Walkersville, Md.). All cell lines were maintained at 37° C. and 5% 602.
  • Tissue Samples and Laser Capture Microdissection Prostate tissues obtained from consented patients that underwent radical prostatectomy were acquired through the Hollings Cancer Center tumor bank in accordance with an Institutional Review Board-approved protocol. This included guidelines for the processing, sectioning, histological characterization, RNA purification and PCR amplification of samples. Following pathologic examination of frozen tissue sections, laser capture microdissection (LCM) was performed to ensure that the tissue samples assayed consisted of pure populations of benign prostate cells. For each tissue section analyzed, LCM was performed at three different regions containing benign tissue and the cells collected were then pooled.
  • LCM laser capture microdissection
  • DEFB1 cDNA was generated from RNA by reverse transcription-PCR.
  • the PCR primers were designed to contain ClaI and KpnI restriction sites.
  • DEFB1 PCR products were restriction digested with ClaI and KpnI and ligated into a TA cloning vector.
  • the TA/DEFB1 vector was then transfected into E. coli by heat shock and individual clones were selected and expanded. Plasmids were isolated by Cell Culture DNA Midiprep (Qiagen, Valencia, Calif.) and sequence integrity verified by automated sequencing.
  • the DEFB1 gene fragment was then ligated into the pTRE2 digested with ClaI and KpnI, which served as an intermediate vector for orientation purposes.
  • the pTRE2/DEFB1 construct was digested with ApaI and KpnI to excise the DEFB1 insert, which was ligated into pIND vector of the Ecdysone Inducible Expression System (Invitrogen, Carlsbad, Calif.) also double digested with ApaI and KpnI.
  • the construct was again transfected into E. coli and individual clones were selected and expanded. Plasmids were isolated and sequence integrity of pIND/DEFB1 was again verified by automated sequencing.
  • RNA Isolation and Quantitative RT-PCR In order to verify DEFB1 protein expression in the cells transfected with DEFB1 construct, RNA was collected after a 24 hour induction period with Ponasterone A (Pon A), Briefly, total RNA was isolated using the SV Total RNA Isolation System (Promega, Madison, Wis.) from approximately 1 ⁇ 10 6 cells harvested by trypsinizing. Here, cells were lysed and total (NA was isolated by centrifugation through spin columns. For cells collected by LCM, total RNA was isolated using the PicoPure RNA Isolation Kit (Arcturus Biosciences, Mt. View, Calif.) following the manufacturer's protocol.
  • Ponasterone A Ponasterone A
  • RNA (0.5 ⁇ g per reaction) from both sources was reverse transcribed into cDNA utilizing random primers (Promega).
  • AMV Reverse Transcriptase II enzyme (500 units per reaction; Promega) was used for first strand synthesis and Tfl DNA Polymerase for second strand synthesis (500 units per reaction; Promega) as per the manufacturer's protocol.
  • 50 pg of cDNA was used per ensuing PCR reaction.
  • Two-step QRT-PCR was performed on cDNA generated using the MultiScribe Reverse Transcripatase from the TaqMan Reverse Transcription System and the SYBR® Green PCR Master Mix (Applied Biosystems).
  • DEFB1 The primer pair for DEFB1 (Table 2) was generated from the published DEFB1 sequence (GenBank Accession No. U50930). Forty cycles of PCR were performed under standard conditions using an annealing temperature of 56° C. In addition, ⁇ -actin (Table 3) was amplified as a housekeeping gene to normalize the initial content of total cDNA. DEFB1 expression was calculated as the relative expression ratio between DEFB1 and ⁇ -actin and was compared in cells lines induced and uninduced for DEFB1 expression, as well as LCM benign prostatic tissue. As a negative control, QRT-PCR reactions without cDNA template were also performed. All reactions were run three times in triplicate.
  • MTT Cell Viability Assay To examine the effects of DEFB1 on cell growth, metabolic 3-[4,5-dimethylthiazol-2yl]-2,5 diphenyl tetrazolium bromide (MTT) assays were performed. PC3, DU145 and LNCaP cells co-transfected with pVgRXR plasmid and pIND/DEFB1 construct or empty pIND vector were seeded onto a 96-well plate at 1-5 ⁇ 10 3 cells per well. Twenty-four hours after seeding, fresh growth medium was added containing 10 ⁇ M Ponasterone A daily to induce DEFB1 expression for 24-, 48- and 72 hours after which the MTT assay was performed according to the manufacturer's instructions (Promega). Reactions were performed three times in triplicate.
  • PC3 and DU145 cells co-transfected with the DEFB1 expression system were grown in 60-mm dishes and induced for 12, 24, and 48 hours with 10 ⁇ M Ponasterone A. Following each incubation period, the medium was collected from the plates (to retain any detached cells) and combined with PBS used to wash the plates. The remaining attached cells were harvested by trypsinization and combined with the detached cells and PBS. The cells were then pelleted at 4° C.
  • Caspase Detection Detection of caspase activity in the prostate cancer cell lines was performed using APO LOGIXTM Carboxyfluorescin Caspase detection kit (Cell Technology, Mountain View, Calif.). Active caspases were detected through the use of a FAM-VAD-FMK inhibitor that irreversibly binds to active caspases. Briefly, DU145 and PC3 cells (1.5-3 ⁇ 105) containing the DEFB1 expression system were plated in 35 mm glass bottom microwell dishes (Matek, Ashland, Mass.) and treated for 24 hours with media only or with media containing PonA as previously described.
  • DEFB1 Expression in Prostate Tissue and Cell Lines were measured by QRT-PCR in benign and malignant prostatic tissue, hPrEC prostate epithelial cells and DU145, PC3 and LNCaP prostate cancer cells. DEFB1 expression was detected in all of the benign clinical samples. The average amount of DEFB1 relative expression was 0.0073. In addition, DEFB1 relative expression in hPrEC cells was 0.0089. There was no statistical difference in DEFB1 expression detected in the benign prostatic tissue samples and hPrEC ( FIG. 1A ). Analysis of the relative DEFB1 expression levels in the prostate cancer cell lines revealed significantly lower levels in DU145, PC3 and LNCaP.
  • relative DEFB1 expression was measured in the adjacent malignant section of prostatic tissue from patient #1215. There were no significant differences in the level of DEFB1 expression observed in the three prostate cancer lines compared to malignant prostatic tissue from patient #1215 ( FIG. 1B ). In addition, expression levels in all four samples were close to the no template negative controls which confirmed little to no endogenous DEFB1 expression (data not shown).
  • QRT-PCR was also performed on the prostate cancer cell lines transfected with the DEFB1 expression system. Following a 24 hour induction period, relative expression levels were 0.01360 in DU145, 0.01503 in PC3 and 0.138 in LNCaP. Amplification products were verified by gel electrophoresis.
  • DEFB1 causes Cell Membrane Permeability and Ruffling: Induction of DEFB1 in the prostate cancer cell lines resulted in a significant reduction in cell number in DU145 and PC3, but had no effect on cell proliferation in LNCaP ( FIG. 2 ). As a negative control, cell proliferation was monitored in all three lines containing empty plasmid. There were no observable changes in cell morphology in DU145, PC3 or LNCaP cells following the addition of PonA. In addition, DEFB1 induction resulted in morphological changes in both DU145 and PC3. Here cells appeared more rounded and exhibited membrane ruffling indicative of cell death. Apoptotic bodies were also present in both lines.
  • the MTT assay showed a reduction in cell viability by DEFB1 in PC3 and DU145 cells, but no significant effect on LNCaP cells ( FIG. 3 ). After 24 hours, relative cell viability was 72% in DU145 and 56% in PC3. Analysis 48 hours after induction revealed 49% cell viability in DU145 and 37% cell viability in PC3. After 72 hours of DEFB1 expression resulted in 44% and 29% relative cell viability in DU145 and PC3 cells, respectively.
  • DEFB1 causes Rapid Caspase-mediated Apoptosis in Late-stage Prostate Cancer Cells
  • FACS analysis was performed. Under normal growth conditions, more than 90% of PC3 and DU145 cultures were viable and non-apoptotic (lower left quadrant) and did not stain with annexin V or PI ( FIG. 4 ).
  • the number of apoptotic cells (lower and upper right quadrants) totaled 10% at 12 hours, 20% at 24 hours, and 44% at 48 hours.
  • Caspase activity was determined by confocal laser microscopic analysis ( FIG. 5 ).
  • DU145 and PC3 cell were induced for DEFB1 expression and activity was monitored based on the binding of green fluorescing FAM-VAD-FMK to caspases in cells actively undergoing apoptosis.
  • Analysis of cells under DIC showed the presence of viable control DU145 (A), PC3 (E) and LNCaP (I) cells at 0 hours.
  • Excitation by the confocal laser at 488 nm produced no detectable green staining which indicates no caspase activity in DU145 (B), PC3 (F) or LNCaP (J).
  • DU145 (C), PC3 (G) and LNCaP (K) cells were again visible under DIC.
  • Confocal analysis under fluorescence revealed green staining in DU145 (D) and PC3 (H) cell indicating caspase activity.
  • LNCaP (L) there was no green staining in LNCaP (L), indicating no induction of apoptosis by DEFB1.
  • DEFB1 is part of an innate immune system involved in tumor immunity.
  • Data presented here demonstrate that DEFB1 expressed at physiological levels is cytotoxic to AR ⁇ hormone refractory prostate cancer cells, but not to AR+hormone sensitive prostate cancer cell nor to normal prostate epithelial cells.
  • DEFB1 is constitutively expressed in normal prostate cells without cytotoxicity, it may be that late-stage AR ⁇ prostate cancer cells possess distinct phenotypic characteristics that render them sensitive to DEFB1 cytotoxicity.
  • DEFB1 is a viable therapeutic agent for the treatment of late-stage prostate cancer, and potentially other cancers as well.
  • This example examines the effects of inhibiting PAX2 expression by RNA interference in prostate cancer cells which differ in p53 gene status.
  • the results demonstrate that the inhibition of PAX2 results in cell death irrespective of p53 status, indicating that there are additional tumor suppressor genes or cell death pathways inhibited by PAX2 in prostate cancer.
  • siRNA Silencing of PAX2 In order to achieve efficient gene silencing, a pool of four complementary short interfering ribonucleotides (siRNAs) targeting human PAX2 mRNA (Accession No. NM — 003989.1), were synthesized (Dharmacon Research, Lafayette, Colo., USA). A second pool of four siRNAs were used as an internal control to test for the specificity of PAX2 siRNAs. Two of the sequences synthesized target the GL2 luciferase mRNA (Accession No. X65324), and two were non-sequence-specific (Table 3).
  • siRNAs complementary short interfering ribonucleotides
  • annealing buffer 100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate
  • Blots were then probed with rabbit anti-PAX2 primary antibody (Zymed, San Francisco, Calif.) at a 1:2000 dilution. After washing, the membranes were incubated with anti-rabbit antibody conjugated to horseradish peroxidase (HRP) (dilution 1:5000; Sigma), and signal detection was visualized using chemilluminescence reagents (Pierce) on an Alpha Innotech Fluorchem 8900. As a control, blots were stripped and reprobed with mouse anti- ⁇ -actin primary antibody (1:5000; Sigma-Aldrich) and HRP-conjugated anti-mouse secondary antibody (1:5000; Sigma-Aldrich) and signal detection was again visualized.
  • HRP-conjugated anti-mouse secondary antibody (1:5000; Sigma-Aldrich
  • Phase Contrast Microscopy The effect of PAX2 knock-down on cell growth was analyzed by phase contrast microscopy.
  • 1-2 ⁇ 104 cells were seeded onto 6 well culture plates (BD Falcon, USA). The following day cells were treated with media only, negative control non-specific siRNA or PAX2 siRNA and allowed to incubate for six days. The cells were then viewed under an inverted Zeiss IM 35 microscope (Carl Zeiss, Germany) at 32 ⁇ magnification. Phase contrast pictures of a field of cells were obtained using the SPOT Insight Mosaic 4.2 camera (Diagnostic Instruments, USA).
  • MTT Cytotoxicity Assay DU145, PC3 and LNCaP cells (1 ⁇ 105) were transfected with 0.5 ⁇ g of the PAX2 siRNA pool or control siRNA pool using Codebreaker transfection reagent according to the manufacturer's protocol (Promega). Next, cell suspensions were diluted and seeded onto a 96-well plate at 1-5 ⁇ 103 cells per well and allowed to grow for 2-, 4- or 6 days. After culture, cell viability was determined by measuring the conversion of 3-[4,5-dimethylthiazol-2yl]-2,5 diphenyl tetrazolium bromide, MTT (Promega), to a colored formazan product. Absorbance was read at 540 nm on a scanning multiwell spectrophotometer.
  • Pan-Caspase detection in the prostate cancer cell lines and quantitative real-time PCR were performed as described in Example 1.
  • the primer pairs for BAX, BID and BAD were generated from the published sequences (Table 4).
  • Reactions were performed in MicroAmp Optical 96-well Reaction Plate (PE Biosystems). Forty cycles of PCR were performed under standard conditions using an annealing temperature of 60° C. Quantification was determined by the cycle number where exponential amplification began (threshold value) and averaged from the values obtained from the triplicate repeats. There was an inverse relationship between message level and threshold value.
  • GAPDH was used as a housekeeping gene to normalize the initial content of total cDNA. Gene expression was calculated as the relative expression ratio between the pro-apoptotic genes and GAPDH. All reactions were carried out in triplicate.
  • siRNA Inhibition of PAX2 Protein In order to confirm that the siRNA effective targeted the PAX2 mRNA, Western Analysis was performed to monitor PAX2 protein expression levels over a six day treatment period. Cells were given a single round of transfection with the pool of PAX2 siRNA. The results confirmed specific targeting of PAX2 mRNA by showing knock-down of PAX2 protein by day four in DU145 ( FIG. 6 a ) and by day six in PC3 ( FIG. 6 b ).
  • Cytotoxicity Assays Cell viability was measured after two-, four-, and six-day exposure times, and is expressed as a ratio of the 570-630 nm absorbance of treated cells divided by that of the untreated control cells ( FIG. 8 ). Relative cell viability following 2 days of treatment was 77% in LNCaP, 82% in DU145 and 78% in PC3. After four days, relative cell viability was 46% in LNCaP, 53% in DU145 and 63% in PC3. After six days of treatment, relative cell viability decreased to 31% in LNCaP, 37% in PC3, and was 53% in DU145. As negative controls, cell viability was measured in after a six day treatment period with negative control non-specific siRNA or transfection reagent alone. For both conditions, there was no statistically significant change in cell viability compared to normal growth media.
  • Pan-Caspase Detection Caspase activity was detected by confocal laser microscopic analysis.
  • DU145, PC3 and LNCaP cells were treated with PAX2 siRNA and activity was monitored based on the binding of FAM-labeled peptide to caspases in cells actively undergoing apoptosis which will be fluoresce green.
  • Analysis of cells with media only under DIC shows the presence of viable DU145 (A), PC3 (E) and LNCaP (I) cells at 0 hours ( FIG. 9 ).
  • Excitation by the confocal laser at 488 nm produced no detectable green staining which indicates no caspase activity in untreated DU145 (B), PC3 (F) or LNCaP (J).
  • DU145 (C), PC3 (G) and LNCaP (K) cells were again visible under DIC.
  • anti-PAX2 siRNAs include, but are not limited to, siRNAs having the sequences of (5′ to 3′ direction):
  • PAX proteins are a family of transcription factors conserved during evolution and able to bind specific DNA sequences through a domains called a “paired domain (PD)” and a “homeodomain (HD).”
  • the PD is a consensus sequence shared by certain PAX proteins (e.g., PAX2 and PAX6).
  • the PD directs DNA binding of amino acids located in the ⁇ 3-helix forming a DNA-Protein complex.
  • the amino acids in the HD recognize and interact specifically with a CCTTG (SEQ ID NO:1) DNA core sequence. Oligonucleotides including this sequence or its complement are expected to be inhibitors of PAX 2 proteins.
  • the oligonucleotide has the sequence of V-CCTTG-W (SEQ ID NO: 12), wherein V is from 1 to 35 contiguous flanking nucleotides of DE-FBI and W is from 1 to 35 nucleotides.
  • the nucleotides can be contiguous nucleotides that normally flank the PAX2 DNA binding site of DEFB1. Alternatively, they can be unrelated to DEFB1, and selected routinely to avoid interference with the recognition sequence
  • oligonucleotides that inhibit PAX2 binding to the DEFB1 promoter include, but are not limited to, oligonucleotide having the sequences of (5′ to 3′ direction):
  • Example 1 demonstrated that there is a high frequency of DEFB1 expression loss in prostate cancer, and that induction of DEFB1 expression results in rapid apoptosis in androgen receptor negative-stage prostate cancer. These data show that DEFB1 plays a role in prostate tumor suppression. In addition, given that it is a naturally occurring component of the immune system of normal prostate epithelium, DEFB1 is expected to be a viable therapeutic agent with little to no side effects.
  • Example 2 demonstrated that inhibition of PAX2 expression results in prostate cancer cell death independent of p53. These data indicate that there is an addition pro-apoptotic factor or tumor suppressor that is inhibited by PAX2.
  • the data show that the oncogenic factor PAX2, which is over-expressed in prostate cancer, is a transcriptional repressor of DEFB1.
  • the purpose of this study is to determine if DEFB1 loss of expression is due to aberrant expression of the PAX2 oncogene, and whether inhibiting PAX2 results in DEFB1-mediated cell death.
  • RNA Isolation and Quantitative RT-PCR were performed as described in Example 1.
  • the primer pair for DEFB1 was generated from the published DEFB1 sequence (Accession No. U50930). Forty cycles of PCR were performed under standard conditions using an annealing temperature of 56° C.
  • GAPDH was amplified as a housekeeping gene to normalize the initial content of total cDNA.
  • DEFB1 expression was calculated as the relative expression ratio between DEFB1 and GAPDH and was compared in cells lines before and after siRNA knock-down of PAX2 expression. All reactions were run three times in triplicate.
  • the pGL3 luciferase reporter plasmid was used to monitor DEFB1 reporter activity.
  • a region 160 bases upstream of the DEFB1 transcription initiation site and included the DEFB1 TATA box.
  • the region also included the GTTCC (SEQ ID NO: 2) sequence which is necessary for PAX2 binding.
  • the PCR primers were designed to contain Kpn1 and NHe1 restriction sites.
  • the DEFB1 promoter PCR products were restriction digested KpnI and NheI and ligated into a similarly restriction digested pGL3 plasmid ( FIG. 2 ).
  • the constructs were transfected into E. coli and individual clones were selected and expanded. Plasmids were isolated and sequence integrity of the DEFB1/pGL3 construct was verified by automated sequencing.
  • Luciferase Reporter Assay Here, 1 ⁇ g of the DEFB1 reporter construct or the control pGL3 plasmid was transfected into 1 ⁇ 10 6 DU145 cells. Next, 0.5 ⁇ 103 cells were seeded onto each well of a 96-well plate and allowed to grow overnight. Then fresh medium was added containing PAX2 siRNA or media only and the cells were incubated for 48 hours. Luciferase was detected by the BrightGlo kit according to the manufacturer's protocol (Promega) and the plates were read on a Veritas automated 96-well luminometer. Promoter activity was expressed as relative luminescence.
  • Control cells were provided fresh media at 24 and 48 h.
  • separate culture slides containing DU145, PC3 and LNCaP were treated with PAX2 siRNA and incubated for 4 days. Following this, cells were washed once with PBS and stained with 2 ml of a mixture (1:1) of AO (Sigma, USA) and EtBr (Promega, USA) (5 ug/ml) solution for 5 min. Following staining, the cells were again washed with PBS. Fluorescence was viewed by a Zeiss LSM 5 Pascal Vario 2 Laser Scanning Confocal Microscope (Carl Zeiss Jena, Germany).
  • the excitation color wheel contain BS505-530 (green) and LP560 (red) filter blocks which allowed for the separation of emitted green light from AO into the green channel and red light from EtBr into the red channel.
  • the laser power output and gain control settings within each individual experiment were identical between control and DEFB1 induced cells.
  • the excitation was provided by a Kr/Ar mixed gas laser at wavelengths of 543 nm for AO and 488 nm for EtBr. Slides were analyzed under 40 ⁇ magnification and digital images were stored as uncompressed TIFF files and exported into Photoshop CS software (Adobe Systems, San Jose, Calif.) for image processing and hard copy presentation.
  • Chromatin immunoprecipitation allows the identification of binding sites for DNA-binding proteins based upon in vivo occupancy of a promoter by a transcription factor and enrichment of transcription factor bound chromatin by immunoprecipitation.
  • a modification of the protocol described by the Farnham laboratory was used; also on line at http://mcardle.oncology.wisc.edu/farnham/).
  • the DU145 and PC3 cell lines over-expresses the PAX2 protein, but does not express DEFB1. Cells were incubated with PBS containing 1.0% formaldehyde for 10 minutes to crosslink proteins to DNA. Samples were then sonicated to yield DNA with an average length of 600 bp.
  • siRNA Inhibition of PAX2 Increases DEFB1 Expression: QRT-PCR analysis of DEFB1 expression before siRNA treatment revealed relative expression levels of 0.00097 in DU145, 0.00001 in PC3, and 0.00004 LNCaP ( FIG. 13 ). Following siRNA knockdown of PAX2, relative expression was 0.03294 (338-fold increase) in DU145, 0.00020 (22.2-fold increase) in PC3 and 0.00019 (4.92-fold increase) in LNCaP. As a negative control, the human prostate epithelial cell line (hPrEC) which is PAX2 null, revealed expression levels at 0.00687 before treatment and 0.00661 following siRNA treatment confirming no statistical change in DEFB1 expression.
  • hPrEC human prostate epithelial cell line
  • DEFB1 Causes Cell Membrane Permeability: Membrane integrity was monitored by confocal analysis ( FIG. 14 ). Here, intact cells stain green due to AO which is membrane permeable. In addition, cells with compromised plasma membranes would stain red by EtBr which is membrane impermeable. Here, uninduced DU145 (A) and PC3 (D) cells stained positively with AO and emitted green color, but did not stain with EtBr. However, DEFB1 induction in both DU145 (B) and PC3 (E) resulted in the accumulation of EtBr in the cytoplasm at 24 hours indicated by the red staining. By 48 hours, DU145 (C) and PC3 (F) possessed condensed nuclei and appeared yellow, which was due to the presence of both green and red staining resulting from the accumulation of AO and EtBr, respectively.
  • Lane 1 contains a 100 bp molecular weight marker.
  • Lane 2 is a positive control representing 160 bp region of the DEFB1 promoter amplified from DU145 before cross-linking and immunoprecipitation.
  • Lane 3 is a negative control representing PCR performed without DNA.
  • Lanes 4 and 5 are negative controls representing PCR from immunoprecipitations performed with IgG from cross-linked DU145 and PC3, respectively.
  • PCR amplification of 25 pg of DNA (lane 6 and 8) and 50 pg of DNA (lane 7 and 9) immunoprecitipated with anti-PAX2 antibody after crosslinking show 160 bp promoter fragment in DU145 and PC3, respectively.
  • DEFB1 The anti-tumoral ability of DEFB1 is evaluated by injecting tumor cells that overexpress DEFB1 into nude mice.
  • DEFB1 is cloned into pBI-EGFP vector, which has a bidirectional tetracycline responsible promoter.
  • Tet-Off Cell lines are generated by transfecting pTet-Off into DU145, PC3 and LNCaP cells and selecting with G418.
  • the pBI-EGFP-DEFB1 plasmid is co-transfected with pTK-Hyg into the Tet-off cell lines and selected with hygromycin. Only single-cell suspensions with a viability of >90% are used. Each animal receives approximately 500,000 cells administered subcutaneously into the right flank of female nude mice.
  • mice There are two groups, a control group injected with vector only clones and a group injected with the DEFB1 over-expressing clones. 35 mice are in each group as determined by a statistician. Animals are weighed twice weekly, tumor growth monitored by calipers and tumor volumes determined using the following formula: volume 0.5 ⁇ (width)2 ⁇ length. All animals are sacrificed by CO2 overdose when tumor size reaches 2 mm3 or 6 months following implantation; tumors are excised, weighed and stored in neutral buffered formalin for pathological examination. Differences in tumor growth between the groups are descriptively characterized through summary statistics and graphical displays. Statistical significance is evaluated with either the t-test or non-parametric equivalent.
  • Hairpin PAX2 siRNA template oligonucleotides utilized in the in vitro studies are utilized to examine the effect of the up-regulation of DEFB1 expression in vivo.
  • the sense and antisense strand (see Table 4) are annealed and cloned into pSilencer 2.1 U6 hygro siRNA expression vector (Ambion) under the control of the human U6 RNA pol III promoter.
  • the cloned plasmid is sequenced, verified and transfected into PC3, Du145, and LNCap cell lines. Scrambled shRNA is cloned and used as a negative control in this study. Hygromycin resistant colonies are selected, cells are introduced into the mice subcutaneously and tumor growth is monitored as described above.
  • the DNA recognition sequence for PAX2 binding resides in the DEFB1 promoter between nucleotides ⁇ 75 and ⁇ 71 [+1 refers to the transcriptional start site].
  • Short oligonucleotides complementary to the PAX2 DNA-binding domain are provided. Examples of such oligonucleotides include the 20-mer and 40-mer oligonucleotides containing the GTTCC (SEQ ID NO: 2) recognition sequence provided below. These lengths were randomly selected, and other lengths are expected to be effective as blockers of binding.
  • oligonucleotides with a scrambled sequence (CTCTG) SEQ ID NO: 17
  • oligonucleotides are transfected into the prostate cancer cells and the HPrEC cells with lipofectamine reagent or Codebreaker transfection reagent (Promega, Inc).
  • lipofectamine reagent or Codebreaker transfection reagent Promega, Inc.
  • double stranded oligonucleotides will be labeled with [ 32 P] dCTP and electrophoretic mobility shift assays are performed.
  • DEFB1 expression is monitored by QRT-PCR and Western analysis following treatment with oligonucleotides. Finally, cell death is detected by MTT assay and flow cytometry as previously described.
  • oligonucleotides of the invention include:
  • This set of alternative inhibitory oligonucleotides represents the recognition sequence (along with the CCTTG (SEQ ID NO: 1) core sequence) for the PAX2 binding domain and homeobox. These include actual sequences from the DEFB1 promoter.
  • the PAX2 gene is required for the growth and survival of various cancer cells including prostate.
  • the inhibition of PAX2 expression results in cell death mediated by the innate immunity component DEFB1.
  • Suppression of DEFB1 expression and activity is accomplished by binding of the PAX2 protein to a GTTCC (SEQ ID NO: 2) recognition site in the DEFB1 promoter. Therefore, this pathway provides a viable therapeutic target for the treatment of prostate cancer.
  • the sequences bind to the PAX2 DNA binding site and block PAX2 binding to the DEFB1 promoter thus allowing DEFB1 expression and activity.
  • the oligonucleotide sequences and experiment described above are examples of and demonstrate a model for the design of additional PAX2 inhibitor drugs.
  • PAX2 regulates their expression and activity as well. Therefore the PAX2 inhibitors disclosed herein have utility in a number of other diseases including those directed related to inflammation including prostatitis and benign prostatic hypertrophy (BPH).
  • BPH benign prostatic hypertrophy
  • the Cre/loxP system has been useful in elucidating the molecular mechanisms underlying prostate carcinogenesis.
  • a DEFB1 Cre conditional KO is used for inducible disruption within the prostate.
  • the DEFB1 Cre conditional KO involves the generation of a targeting vector containing loxP sites flanking DEFB1 coding exons, targeted ES cells with this vector and the generation of germline chimeric mice from these targeted ES cells.
  • Heterozygotes are mated to prostate-specific Cre transgenics and heterozygous intercross is used to generate prostate-specific DEFB1 KO mice.
  • DEFB1-transgenic mice are treated with these carcinogenic compounds via intra-gastric administration or i.v. injection for prostate adenoma and adenocarcinoma induction studies. Prostate samples are studied for differences in tumor growth and changes gene expression though histological, immunohistological, mRNA and protein analyses.
  • PAX2 inducible GOF mice PAX2 GOF (bi-transgenic) and wild-type (mono-transgenic) littermates are administered doxycycline (Dox) from 5 weeks of age to induce prostate-specific PAX2 expression.
  • Dox doxycycline
  • PROBASIN-rtTA mono-transgenic mice prostate cell-specific expression of tet-dependent rtTA inducer
  • bi-transgenic mice are fed Dox via the drinking water (500 mg/L freshly prepared twice a week).
  • Initial experiments verify low background levels, good inducibility and cell-type specific expression of PAX2 and the EGFP reporter using transgenic founder line in bi-transgenic mice.
  • Experimental group sizes 5-7 age- and sex-matched individuals in each group (wild-type and GOF) allow for statistical significance.
  • prostate tissues are collected initially at weekly intervals for analysis and comparison, to determine carcinogenic time parameters.
  • PROBASIN-rtTA transgenic mice are genotyped using the following PCR primers and conditions:
  • PROBASIN5 forward
  • 5′-ACTGCCCATTGCCCAAACAC-3′ 5′-ACTGCCCATTGCCCAAACAC-3′
  • RTTA3 reverse
  • 5′-AAAATCTTGCCAGCTTTCCCC-3′ 5′-AAAATCTTGCCAGCTTTCCCC-3′
  • PAX2 inducible transgenic mice are genotyped using the following PCR primers and conditions: PAX2 For 5′-GTCGGTITACGGAGCGGACCGGAG-3′ (SEQ ID NO: 28);
  • Immortomoouse hemizygotes are be genotyped using the following PCR
  • primers and conditions in Immol1, 5′-GCGCTTGTGTCGCCATTGTATTC-3′ (SEQ ID NO: 30); Immol2, 5′-GTCACACCACAGAAGTAAGGTTCC-3′ (SEQ ID NO: 31);
  • PAX2 For 5′-GTCGGTTACGGAGCGGACCGGAG-3′; (SEQ ID NO: 32) PAX2Rev 5′-CACAGAGCATTGGCGATCTCGATGC-3′; (SEQ ID NO: 33)
  • Cancer chemoprevention is defined as the prevention of cancer or treatment at the pre-cancer state or even earlier.
  • the long period of progression to invasive cancer is a major scientific opportunity but also an economic obstacle to showing the clinical benefit of candidate chemopreventive drugs. Therefore, an important component of chemopreventive agent development research in recent years has been to identify earlier (than cancer) end points or biomarkers that accurately predict an agent's clinical benefit or cancer incidence-reducing effect.
  • IEN is an early end point such as in prostate cancer.
  • the PAX2/DEFB1 pathway is deregulated during TEN and perhaps at even an earlier histopathological state makes it a powerful predictive biomarker and an excellent target for chemoprevention of cancer. Shown are a number of compounds that suppress PAX2 and increases DEFB1 expression that may have utility as chemoprevention agents for prostate cancer.
  • AngII Angiotensin II
  • AT1R Angiotensin Type I receptor
  • AT2R Angiotensin Type II receptor
  • AngII has been shown to play a role in various pathological situations involving tissue remodeling, such as wound healing, cardiac hypertrophy and development.
  • tissue remodeling such as wound healing, cardiac hypertrophy and development.
  • recent studies have revealed local expression of several components of the Renin-Angiotensin System (RAS) in various cancer cells and tissues including the prostate.
  • RAS Renin-Angiotensin System
  • Upregulation of AT1R provides a considerable advantage to cancer cells that have learn to evade apoptosis and growth regulatory elements.
  • Cells were treated with 5 or 10 uM of AngII, 5 uM of the ATR1 antagonist Los, 5 uM of the ATR2 antagonist PD123319, 25 uM of the MEK inhibitor U0126, 20 uM of the MEK/ERK inhibitor PD98059 or 250 ⁇ M of the AMP kinase inducer AICAR.
  • blots were stripped and re-probed with mouse anti- ⁇ -actin primary antibody (1:5000; Sigma-Aldrich) and HRP-conjugated anti-mouse secondary antibody (1:5000; Sigma-Aldrich), and signal detection was again visualized.
  • Thymidine Incorporation Proliferation of cells was determined by [ 3 H] thymidine ribotide ([ 3 H] TdR) incorporation into DNA. 0.5 ⁇ 10 6 cells/well of suspension DU145 cells were plated in their appropriate media. Cells were incubated for 72 hrs with or without the presence of AngII at the indicated concentrations. Cells were exposed to 37 kBq/ml [methyl- 3 H] thymidine in the same medium for 6 hours. The adherent cells were fixed by 5% trichloroacetic acid and lysed in SDS/NaOH lysis buffer overnight. Radioactivity was measured by Beckman LS3801 liquid scintillation counter (Canada). Suspension cell culture was harvested by cell harvester (Packard instrument Co., Meriden, Conn.), and radioactivity was measured by 1450 microbeta liquid scintillation counter (PerkinElmer Life Sciences).
  • PAX2 expression was examined following treatment with AngII over a 30 min to 48 hour period. As shown in FIG. 19 , PAX2 expression progressively increased over time following AngII treatment. Blocking RAS signaling by treating DU145 with Los significantly reduced PAX2 expression ( FIG. 20A ). Here, PAX2 expression was 37% after 48 hours and was 50% after 72 hours of Los treatment compared to untreated control DU145 cells ( FIG. 21 ). It is known that the AT2R receptor oppose the action of the AT1R. Therefore, the effect of blocking the AT2R receptor on PAX2 expression was examined.
  • AngII directly affects the proliferation of prostate cancer cells through AT1R-mediated activation of MAPK and STAT3 phosphorylation.
  • Treatment of DU145 with AngII resulted in a two- to three-fold increase in proliferation rate ( FIG. 21 ).
  • Treatment with Los decreased proliferated rates by 50%.
  • blocking the AT1R receptor by pre-treating with Los for 30 min suppressed the effect of AngII on proliferation.
  • PAX2 expression is regulated by STAT3 which is a down-stream target of ERK.
  • STAT3 is a down-stream target of ERK.
  • Treatment of DU145 with Los, U0126, and PD98059 reduced phospho-STAT3 protein levels ( FIG. 23C ).
  • AICAR 5-Aminoimidazole-4-carboxamide-1- ⁇ -4-ribofuranoside
  • PAX2 was regulated by the AT1R in prostate cancer ( FIG. 26 ).
  • deregulated RAS signaling resulted in increased PAX2 oncogene expression, and a decrease in the expression of DEFB1 tumor suppressor. Therefore, the use of AT1R antagonists decreases PAX2 expression and results in increased prostate cancer cell death via re-expression of DEFB1 ( FIG. 27 ).
  • PAX2-DEFB1 Expression Level as a Grading Tool for Prostate Tissue and Predictor of Prostate Cancer Development
  • RNA samples were eluted, quantitated, and QRT-PCR is performed as previously mentioned to compare PAX2 and DEFB1 expression ratios.
  • PAX2 and DEFB1 expression levels in normal, PIN and cancerous tissues from separate patients were calculated and compared ( FIG. 29 ).
  • PAX2 expression levels relative to GAPDH internal control ranged between 0 and 0.2 in normal (benign) tissue, 0.2 and 0.3 in PIN, and between 0.3 and 0.5 in cancerous (malignant) tissue ( FIG. 30 ).
  • DEFB1 there was an inverse relationship compared to PAX2.
  • DEFB1 expression levels relative to GAPDH internal control ranged between 0.06 and 0.005 in normal (benign) tissue, 0.005 and 0.003 in PIN, and between 0.003 and 0.001 in cancerous (malignant) tissue.
  • a predictive scale (designated as the “Donald predictive factor” or “DPF”) which utilizes the PAX2-DEFB1 expression ratio as a prognosticator of benign, precancerous (PIN) and malignant prostate tissue.
  • Tissues with PAX2-DEFB1 ratios between 0 and 39 based on the DPF will represent normal (pathologically benign).
  • Tissue with a PAX2-DEFB1 ratio between 40 and 99 will represent PIN (pre-cancerous) based on the DPF scale.
  • tissue with a PAX2-DEFB1 ratio between 100 and 500 will be malignant (low to high grade cancer).
  • CTCs circulating tumor cells
  • Tissue samples and laser capture microdissection Prostate tissues were obtained from patients who provided informed consent prior to undergoing radical prostatectomy. Samples were acquired through the Hollings Cancer Center tumor bank in accordance with an Institutional Review Board-approved protocol. This included guidelines for the processing, sectioning, histological characterization, RNA purification and PCR amplification of samples. Prostate specimens received from the surgeons and pathologists were immediately frozen in OCT compound. Each OCT block was cut to produce serial sections which were stained and examined. Areas containing benign cells, prostatic intraepithelial neoplasia (PIN), and cancer were identified and used to guide our selection of regions from unstained slides using the Arcturus PixCell II System (Sunnyvale, Calif.).
  • PIN prostatic intraepithelial neoplasia
  • RNA quantity and quality was evaluated using sets of primers that produce 5′ amplicons.
  • the sets include those for the ribosomal protein L32 (the 31 amplicon and the 5′ amplicon are 298 bases apart), for the glucose phosphate isomerase (391 bases apart), and for the glucose phosphate isomerase (842 bases apart). Ratios of 0.95 to 0.80 were routinely obtained for these primer sets using samples from a variety of prepared tissues. Additional tumor and normal samples were grossly dissected by pathologists, snap frozen in liquid nitrogen and evaluated for hBD-1 and cMYC expression.
  • hBD-1 cDNA was generated from RNA by reverse transcription-PCR using primers generated from the published hBD-1 sequence (accession no. U50930) (Ganz, 2004). The PCR primers were designed to contain ClaI and KpnI restriction sites. hBD-1 PCR products were restriction digested with ClaI and KpnI and ligated into a TA cloning vector. The TA/hBD1 vector was then transfected into the XL-1 Blue strain of E. coli by heat shock and individual clones were selected and expanded. Plasmids were isolated by Cell Culture DNA Midiprep (Qiagen, Valencia, Calif.) and sequence integrity verified by automated sequencing.
  • the hBD-1 gene fragment was then ligated into the pTRE2 digested with ClaI and KpnI, which served as an intermediate vector for orientation purposes.
  • the pTRE2/hBD-1 construct was digested with ApaI and KpnI to excise the hBD-1 insert.
  • the insert was ligated into pIND vector of the Ecdysone Inducible Expression System (Invitrogen, Carlsbad, Calif.) also double digested with ApaI and KpnI.
  • the construct was transfected into E. coli and individual clones were selected and expanded. Plasmids were isolated and sequence integrity of pIND/hBD-1 was again verified by automated sequencing.
  • Transfection Cells (1 ⁇ 10 6 ) were seeded onto 100-mm Petri dishes and grown overnight. Next, the cells were co-transfected using Lipofectamine 2000 (Invitrogen) with 1 ⁇ g of pvgRXR plasmid, which expresses the heterodimeric ecdysone receptor, and 1 kg of the pIND/hBD-1 vector construct or pIND/ ⁇ -galactosidase ( ⁇ -gal) control vector in Opti-MEM media (Life Technologies, Inc.). Transfection efficiency was determined by inducing ⁇ -gal expression with Ponasterone A (PonA) and staining cells with a ⁇ -galactosidase detection kit (Invitrogen). Assessment of transfection efficiency by counting positive staining (blue) colonies which demonstrated that 60-85% of cells expressed ⁇ -galactosidase for the cell lines.
  • Lipofectamine 2000 Invitrogen
  • pvgRXR plasmid which expresses the heterod
  • DU145 and hPrEC cells were seeded onto 2-chamber culture slides (BD Falcon, USA) at 1.5-2 ⁇ 104 cells per chamber.
  • DU145 cells transfected with pvgRXR alone (control) or with the hBD-1 plasmid were induced for 18 hours with media containing 10 ⁇ M Pon A, while untransfected cells received fresh growth media. Following induction, cells were washed in 1 ⁇ PBS and fixed for 1 hour at room temperature with 4% paraformaldehyde.
  • RNA isolation and quantitative RT-PCR were performed as described in Example 1.
  • the primer pairs for hBD-1 and c-MYC were generated from the published sequences (Table 6). Forty cycles of PCR were performed under standard conditions using an annealing temperature of 56.4° C. for hBD-1 and c-MYC and 55° C. for PAX2.
  • ⁇ -actin (Table 6) was amplified as a housekeeping gene to normalize the initial content of total cDNA. Gene expression in benign prostate tissue samples was calculated as the expression ratio compared to ⁇ -actin.
  • hBD-1 expression in malignant prostate tissue, hPREC prostate primary culture, and prostate cancer cell lines before and after induction were calculated relative to the average level of hBD-1 expression in hPrEC cells.
  • QRT-PCR reactions without cDNA template were also performed. All reactions were run a minimum of three times.
  • MTT cell viability assay was performed as described in Example 1.
  • siRNA silencing of PAX2 was performed as described in Example 2. siRNA molecules were coated with CodeBreaker transfection reagent (Promega, Inc.) according to manufacturer's directions prior to treatment.
  • hBD-1 expression in prostate tissue 82% of prostate cancer frozen tissue sections analyzed exhibited little or no expression of hBD-1 (Donald et al., 2003).
  • QRTPCR analysis was performed on normal prostate tissue obtained by gross dissection or LCM of normal prostate tissue adjacent to malignant regions which were randomly chosen.
  • hBD-1 was detected in all of the gross dissected normal clinical samples with a range of expression that represents approximately a 6.6-fold difference in expression levels ( FIG. 31A ).
  • LCM captured normal tissue samples expressed hBD-1 at levels in a range that represents a 32-fold difference in expression ( FIG. 31B ).
  • hBD-1 expression in prostate cell lines To verify upregulation of hBD-1 in the prostate cancer cell lines after transfection with the hBD-1 expression system, QRTPCR was performed. In addition, no template negative controls were also performed, and amplification products were verified by gel electrophoresis. Here, hBD-1 expression was significantly lower in the prostate cancer cell lines compared to hPrEC cells. Following a 24 hours induction period, relative expression levels of hBD-1 significantly increased in DU145, PC3 and LNCaP as compared to the cell lines prior to hBD-1 induction ( FIG. 32A ).
  • hBD-1 expressing hPrEC prostate epithelial cells were also examined. Cells were stained with primary antibody against hBD-1 and protein expression was monitored based on the green fluorescence of the secondary antibody ( FIG. 32B ). Analysis of cells under DIC verify the presence of hPrEC cells and DU145 cells induced for hBD-1 expression at 18 hours. Excitation by the confocal laser at 488 nm produced revealed green fluorescence indicating the presence of hBD-1 protein in hPrEC as a positive control.
  • MTT assay was performed to assess the effect of hBD-1 expression on relative cell viability in DU145, PC3, PC3/AR+ and LNCaP prostate cancer cell lines. MTT analysis with empty vector exhibited no statistical significant change in cell viability. Twenty-four hours following hBD-1 induction, relative cell viability was 72% in DU145 and 56% in PC3 cells, and after 48 hours cell viability was reduced to 49% in DU145 and 37% in PC3 cells ( FIG. 33A ). Following 72 hours of hBD-1 induction, relative cell viability decreased further to 44% in DU145 and 29% PC3 cells. Conversely, there was no significant effect on the viability of LNCaP cells.
  • DU145 cells For DU145 cells, the number of cells undergoing early apoptosis and late apoptosis/necrosis totaled 12% after 12 hours, 34% at 24 hours, and 59% after 48 hours of induction. No increase in apoptosis was observed in cells containing empty plasmid following induction with Pon A. Annexin V and propidium iodide uptake studies have demonstrated that hBD-1 has cytotoxic activity against DU145 and PC3 prostate cancer cells and results indicate apoptosis as a mechanism of cell death.
  • hBD-1 causes alterations in membrane integrity and caspase activation: It was investigated whether the cell death observed in prostate cancer cells after hBD-1 induction is caspase-mediated apoptosis. To better understand the cellular mechanisms involved in hBD-1 expression, confocal laser microscopic analysis was performed ( FIG. 5 ) on DU145 and LNCaP cells induced for hBD-1 expression. Pan-caspase activation was monitored based on the binding and cleavage of green fluorescing FAM-VAD-FMK to caspases in cells actively undergoing apoptosis. Analysis of cells under DIC showed the presence of viable control DU145 ( FIG. 5A ) and LNCaP ( FIG. 5E ) cells at 0 h.
  • hBD-1 and cMYC expression levels QRT-PCR analysis was performed on LCM prostate tissue sections from three patients ( FIG. 34 ).
  • patient #1457 hBD-1 expression exhibited a 2.7-fold decrease from normal to PIN, a 3.5-fold decrease from PIN to tumor and a 9.3-fold decrease from normal to tumor ( FIG. 34A ).
  • cMYC expression followed a similar expression pattern in patient #1457 where expression decreased by 1.7-fold from normal to PIN, 1.7-fold from PIN to tumor and 2.8-fold from normal to tumor ( FIG. 34B ).
  • FIG. 34B there was a statistically significant decrease in cMYC expression in the other two patients.
  • Patient #1569 had a 2.3-fold decrease from normal to PIN, while in patient #1586 there was a 1.8-fold decrease from normal to PIN, a 4.3-fold decrease from PIN to tumor and a 7.9-fold decrease from normal to tumor.
  • Induction of hBD-1 expression following PAX inhibition: To further examine the role of PAX2 in regulating hBD-1 expression, siRNA was utilized to knockdown PAX2 expression and QRT-PCR performed to monitor hBD-1 expression. Treatment of hPrEC cells with PAX2 siRNA exhibited no effect on hBD-1 expression ( FIG. 35 ). However, PAX2 knockdown resulted in a 42-fold increase in LNCaP, a 37-fold increase in PC3 and a 1026-fold increase in DU145 expression of hBD-1 compared to untreated cells. As a negative control, cells were treated with non-specific siRNA which had no significant effect on hBD-1 expression.
  • Cell lines The cancer cell lines PC3, DU145 and LNCaP, which all differ in p53 mutational status (Table 7) were cultured as described in Example 1.
  • siRNA silencing of PAX2 and Western analysis were performed as described in Example 2. Blots were then probed with rabbit anti-PAX2 primary antibody (Zymed, San Francisco, Calif.) at a 1:1000 dilution. After washing, the membranes were incubated with anti-rabbit antibody conjugated to horseradish peroxidase (P) (dilution 1:5000; Sigma), and signal detection was visualized using chemiluminescence reagents (Pierce) on an Alpha Innotech Fluorchem 8900.
  • P horseradish peroxidase
  • blots were stripped and reprobed with mouse anti- ⁇ -actin primary antibody (1:5000; Sigma-Aldrich) and HRP-conjugated anti-mouse secondary antibody (1:5000; Sigma-Aldrich), and signal detection was again visualized.
  • Pan-caspase detection and Quantitative real-time RT-PCR were performed as described in Example 1.
  • the primer pairs for BAX, BID, BCL-2, AKT and BAD were generated from the published sequences (Table 8).
  • Reactions were performed in MicroAmp Optical 96-well Reaction Plate (PE Biosystems). Forty cycles of PCR were performed under standard conditions using an annealing temperature of 60° C. Quantification was determined by the cycle number where exponential amplification began (threshold value) and averaged from the values obtained from the triplicate repeats. There was an inverse relationship between message level and threshold value.
  • GAPDH was used as a housekeeping gene to normalize the initial content of total cDNA. Relative expression was calculated as the ratio between each genes and GAPDH. All reactions were carried out in triplicate.
  • Membrane permeability assay was performed as described in Example 3. PC3 and LNCaP cells were transfected with PAX2 siRNA, non-specific siRNA or media only.
  • PAX2 protein expression was examined by Western analysis in HPrEC prostate primary culture and in LNCaP, DU145 and PC3 prostate cancer cell lines. Here, PAX2 protein was detected in all of the prostate cancer cell lines ( FIG. 36A ). However, no PAX2 protein was detectable in HPrEC. Blots were stripped and re-probed for ⁇ -actin as internal control to ensure equal loading. PAX2 protein expression was also monitored after selective targeting and inhibition by PAX2 specific siRNA in DU145, PC3 and LNCaP prostate cancer cell lines. Cells were given a single round of transfection with the pool of PAX2 siRNA over a 6-day treatment period. PAX2 protein was expressed in control cells treated with media only. Specific targeting of PAX2 mRNA was confirmed by observing knockdown of PAX2 protein in all three cell lines ( FIG. 36B ).
  • Detection of pan-caspase activity was detected by confocal laser microscopic analysis.
  • LNCaP, DU145 and PC3 cells were treated with PAX2 siRNA and activity was monitored based on the binding of FAM-labeled peptide to caspases in cells actively undergoing apoptosis which will be fluoresce green.
  • Analysis of cells with media only shows the presence of viable LNCaP, DU145 and PC3 cells, respectively.
  • Excitation by the confocal laser at 488 um produced no detectable green staining which indicates no caspase activity in the untreated cells ( FIGS. 39A , 39 C and 39 E, respectively).
  • Following 4 days of treatment with PAX2 siRNA LNCaP, DU145 and PC3 cells under fluorescence presented green staining indicating caspase activity ( FIGS. 39B , 39 D and 39 F, respectively).
  • LNCaP, DU145 and PC3 cells were treated with siRNA against PAX2 for 4 days and expression of both pro- and anti-apoptotic factors were measured by QRTPCR.
  • analysis of BAD revealed a 2-fold in LNCaP, 1.58-fold in DU145 and 1.375 in PC3 ( FIG. 40A ).
  • Expression levels of BID increased by 1.38-fold in LNCaP and a 1.78-fold increase in DU145, but there was no statistically significant difference in BID observed in PC3 after suppressing PAX2 expression ( FIG. 40B ).
  • Analysis of the anti-apoptotic factor AKT revealed a 1.25-fold decrease in expression in LNCaP and a 1.28-fold decrease in DU145 following treatment but no change was observed in PC3 ( FIG. 40C ).
  • Membrane integrity was monitored by confocal analysis in LNCaP, DU145 and PC3 cells.
  • intact cells stained green due to AO which is membrane permeable, while cells with compromised plasma membranes would stained red due to incorporation of membrane impermeable EtBr into the cytoplasm, and yellow due to co-localization of AO and EtBr in the nuclei.
  • Untreated LNCaP, DU145 and PC3 cells stained positively with AO and emitted green color, but did not stain with EtBr. Following PAX2 knockdown, there were no observable alterations to membrane integrity in LNCaP cells as indicated by positive green fluorescence with AO and absence of red EtBr fluorescence.
  • LNCaP cells can be undergoing apoptotic, but not necrotic cell death following PAX2 knockdown.
  • PAX2 knockdown in DU145 and PC3 resulted in the accumulation of EtBr in the cytoplasm as indicated by the red staining.
  • both DU145 and PC3 possessed condensed nuclei which appeared yellow due to the co-localization of green and red staining from AO and EtBr, respectively.
  • PAX2 and DEFB-1 expression will be determined in breast biopsy samples of ductal or lobular intraepithelial neoplasia, and in the following breast cancer cell lines:
  • BT-20 Isolated from a primary invasive ductal carcinoma; cell express E-cadherin, ER, EGFR and uPA.
  • BT-474 Isolated from a primary invasive ductal carcinoma; cell express E-cadherin, ER, PR, and have amplified HER2/neu.
  • Hs578T Isolated from a primary invasive ductal carcinoma; a cell line was also established from normal adjacent tissue, termed Hs578Bst.
  • MCF-77 Established from a pleural effusion.
  • the cells express ER and are the most common example of estrogen-responsive breast cancer cells.
  • MDA-MB-231 Established from a pleural effusion.
  • the cells are ER-negative, E-cadherin negative and highly invasive in in vitro assays.
  • MDA-MB-361 Established from a brain metastasis. The cells express ER, PR, EGFR and HER2/neu.
  • MDA-MB-435 Established from a pleural effusion.
  • the cells are ER-negative, E-cadherin negative, and are highly invasive and metastatic in immunodeficient mice.
  • MDA-MB-468 Established from a pleural effusion. The cells have amplified EGFR and are ER-negative.
  • SK-BR-3 Established from a pleural effusion. The cells have amplified HER/2neu, express EGFR and are ER-negative.
  • T-47D established from a pleural effusion. The cells retain expression of E-cadherin, ER and PR.
  • ZR-75-1 Established from ascites fluid.
  • the cells express ER, E-cadherin, HER2/neu and VEGF.
  • the PAX2-to-DEFB-1 expression ratio will be determined using the methods described in Example 9.
  • DEFB1 will be expressed in breast cancer cells using methods described in Example 1. The cell viability and caspase activity will be determined as described in Example 1.
  • PAX2 expression in breast cancer cells will be inhibited using the siRNA described in Example 2.
  • the expression levels of pro-apoptotic genes such as BAX, BID and BAD, the cell viability and caspase activity will be determined as described in Example 2.
  • the anti-tumoral ability of DEFB1 will be evaluated by injecting breast cancer cells that overexpress DEFB1 into nude mice.
  • Breast cancer cells will be transfected with an expression vector carrying the DEFB 1 gene.
  • Cells expressing the exogenous DEFB1 gene will be selected and cloned. Only single-cell suspensions with a viability of >90% are used.
  • Each animal receives approximately 500,000 cells administered subcutaneously into the right flank of female nude mice. There are two groups, a control group injected with vector only clones and a group injected with the DEFB1 over-expressing clones. 35 mice are in each group as determined by a statistician.
  • Hairpin PAX2 siRNA template oligonucleotides utilized in the in vitro studies are utilized to examine the effect of the up-regulation of DEFB1 expression in vivo.
  • the sense and antisense strand (see Table 3) are annealed and cloned into pSilencer 2.1 U6 hygro siRNA expression vector (Ambion) under the control of the human U6 RNA pol III promoter.
  • the cloned plasmid is sequenced, verified and transfected into breast cancer cell lines. Scrambled shRNA is cloned and used as a negative control in this study. Hygromycin resistant colonies are selected, cells are introduced into the mice subcutaneously and tumor growth is monitored as described above.
  • the alternative inhibitory oligonucleotides described in Example 6 will be transfected into the breast cancer cells with lipofectamine reagent or Codebreaker transfection reagent (Promega, Inc).
  • lipofectamine reagent or Codebreaker transfection reagent Promega, Inc.
  • double stranded oligonucleotides will be labeled with [ 32 P] dCTP and electrophoretic mobility shift assays are performed DEFB1 expression will be monitored by QRT-PCR and Western analysis following treatment with oligonucleotides. Finally, cell death will be detected by MTT assay and flow cytometry as previously described.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Hospice & Palliative Care (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
US12/546,292 2005-10-14 2009-08-24 Detecting pax2 for the diagnosis of breast cancer Abandoned US20100029504A1 (en)

Priority Applications (31)

Application Number Priority Date Filing Date Title
US12/546,292 US20100029504A1 (en) 2007-01-16 2009-08-24 Detecting pax2 for the diagnosis of breast cancer
AP2012006182A AP3331A (en) 2009-08-24 2009-08-25 Detecting PAX2 for the diagnosis of breast cancer
CA2771993A CA2771993A1 (en) 2009-08-24 2009-08-25 Detecting pax2 for the diagnosis of breast cancer
RU2012111372/10A RU2522485C2 (ru) 2009-08-24 2009-08-25 Регистрация рах2 для диагностики рака молочной железы
JP2012526698A JP2013510558A (ja) 2009-08-24 2009-08-25 乳癌の診断を目的としたｐａｘ２の検出
CN200980161426.2A CN102648287B (zh) 2009-08-24 2009-08-25 检测pax2用于诊断乳腺癌
NZ599004A NZ599004A (en) 2009-08-24 2009-08-25 Detecting pax2 for the diagnosis of breast cancer
AU2009351638A AU2009351638B2 (en) 2009-08-24 2009-08-25 Detecting PAX2 for the diagnosis of breast cancer
EP09848828.1A EP2475779B1 (en) 2009-08-24 2009-08-25 Detecting pax2 for the diagnosis of breast cancer
PCT/US2009/054913 WO2011025475A1 (en) 2009-08-24 2009-08-25 Detecting pax2 for the diagnosis of breast cancer
AP2012006181A AP3412A (en) 2009-08-24 2010-02-19 Targeting pax2 for the treatment of breast cancer
AU2010286924A AU2010286924B2 (en) 2009-08-24 2010-02-19 Targeting PAX2 for the treatment of breast cancer
CN201410056507.9A CN104083772A (zh) 2009-08-24 2010-02-19 靶向pax2用于治疗乳腺癌
NZ599005A NZ599005A (en) 2009-08-24 2010-02-19 Targeting pax2 for the treatment of breast cancer
CN2010800373971A CN102481379A (zh) 2009-08-24 2010-02-19 靶向pax2用于治疗乳腺癌
PCT/US2010/024740 WO2011025556A1 (en) 2009-08-24 2010-02-19 Targeting pax2 for the treatment of breast cancer
RU2016133412A RU2016133412A (ru) 2009-08-24 2010-02-19 Целенаправленное воздействие на pax2 для лечения рака молочной железы
CA2772036A CA2772036A1 (en) 2009-08-24 2010-02-19 Targeting pax2 for the treatment of breast cancer
RU2012111271/15A RU2012111271A (ru) 2009-08-24 2010-02-19 Целенаправленное воздействие на рах2 для лечения рака молочной железы
EP20200194.7A EP3811950A1 (en) 2009-08-24 2010-02-19 Targeting pax2 for the treatment of breast cancer
JP2012526740A JP2013503162A (ja) 2009-08-24 2010-02-19 乳癌の治療を目的としたｐａｘ２ターゲティング
EP10812443.9A EP2470217B1 (en) 2009-08-24 2010-02-19 Targeting pax2 for the treatment of breast cancer
US13/310,930 US20120071347A1 (en) 2005-10-14 2011-12-05 Compositions and methods for monitoring and detecting cancerous conditions
IL218285A IL218285A (en) 2009-08-24 2012-02-23 2pax detection for breast cancer diagnosis
IL218286A IL218286A (en) 2009-08-24 2012-02-23 2pax direction to treat breast cancer
ZA2012/02169A ZA201202169B (en) 2009-08-24 2012-03-23 Targeting pax2 for the treatment of breast cancer
ZA2012/02170A ZA201202170B (en) 2009-08-24 2012-03-23 Detecting pax2 for the diagnosis of breast cancer
US13/606,917 US8722367B2 (en) 2007-01-16 2012-09-07 Detecting PAX2 for the diagnosis of breast cancer
US13/607,040 US8623617B2 (en) 2007-01-16 2012-09-07 Detecting PAX2 for the diagnosis of breast cancer
HK13102262.2A HK1174955A1 (en) 2009-08-24 2013-02-22 Detecting pax2 for the diagnosis of breast cancer pax2
JP2015142631A JP2016000041A (ja) 2009-08-24 2015-07-17 乳癌の診断を目的としたｐａｘ２の検出

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88514207P 2007-01-16 2007-01-16
PCT/US2008/051168 WO2008089236A2 (en) 2007-01-16 2008-01-16 Compositions and methods for diagnosing, treating, and preventing prostate conditions
US44019309A 2009-03-13 2009-03-13
US12/546,292 US20100029504A1 (en) 2007-01-16 2009-08-24 Detecting pax2 for the diagnosis of breast cancer

Related Parent Applications (3)

Application Number Title Priority Date Filing Date
US12/440,193 Continuation-In-Part US8088603B2 (en) 2007-01-16 2008-01-16 Compositions and methods for diagnosing, treating, and preventing prostate conditions
PCT/US2008/051168 Continuation-In-Part WO2008089236A2 (en) 2005-10-14 2008-01-16 Compositions and methods for diagnosing, treating, and preventing prostate conditions
US44019309A Continuation-In-Part 2005-10-14 2009-03-13

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US12/090,191 Continuation-In-Part US7964577B2 (en) 2005-10-14 2006-10-16 Targeting PAX2 for the induction of DEFB1-mediated tumor immunity and cancer therapy
PCT/US2006/040215 Continuation-In-Part WO2007047512A2 (en) 2005-10-14 2006-10-16 Inhibition of pax2 by defb1 induction as a therapy for cancer
US13/607,040 Continuation US8623617B2 (en) 2007-01-16 2012-09-07 Detecting PAX2 for the diagnosis of breast cancer
US13/606,917 Continuation US8722367B2 (en) 2007-01-16 2012-09-07 Detecting PAX2 for the diagnosis of breast cancer

Publications (1)

Publication Number Publication Date
US20100029504A1 true US20100029504A1 (en) 2010-02-04

Family

ID=43628273

Family Applications (3)

Application Number Title Priority Date Filing Date
US12/546,292 Abandoned US20100029504A1 (en) 2005-10-14 2009-08-24 Detecting pax2 for the diagnosis of breast cancer
US13/607,040 Active - Reinstated US8623617B2 (en) 2007-01-16 2012-09-07 Detecting PAX2 for the diagnosis of breast cancer
US13/606,917 Active 2028-01-31 US8722367B2 (en) 2007-01-16 2012-09-07 Detecting PAX2 for the diagnosis of breast cancer

Family Applications After (2)

Application Number Title Priority Date Filing Date
US13/607,040 Active - Reinstated US8623617B2 (en) 2007-01-16 2012-09-07 Detecting PAX2 for the diagnosis of breast cancer
US13/606,917 Active 2028-01-31 US8722367B2 (en) 2007-01-16 2012-09-07 Detecting PAX2 for the diagnosis of breast cancer

Country Status (13)

Country Link
US (3) US20100029504A1 (ru)
EP (1) EP2475779B1 (ru)
JP (2) JP2013510558A (ru)
CN (1) CN102648287B (ru)
AP (1) AP3331A (ru)
AU (1) AU2009351638B2 (ru)
CA (1) CA2771993A1 (ru)
HK (1) HK1174955A1 (ru)
IL (1) IL218285A (ru)
NZ (1) NZ599004A (ru)
RU (1) RU2522485C2 (ru)
WO (1) WO2011025475A1 (ru)
ZA (1) ZA201202170B (ru)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013085482A1 (en) * 2011-12-05 2013-06-13 Phigenix, Inc. Compositions and methods for monitoring and detecting cancerous conditions
CN115724966A (zh) * 2022-08-22 2023-03-03 北京中杉金桥生物技术有限公司 一种抗人配对盒基因2兔单克隆抗体、制备方法及其应用

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106527A1 (en) * 2015-12-15 2017-06-22 Case Western Reserve University Epithelial cancer evaluation using beta defensin
US10828830B2 (en) * 2015-12-30 2020-11-10 Revotek Co., Ltd Bioprinter
RU2623857C1 (ru) * 2016-06-22 2017-06-29 федеральное государственное бюджетное образовательное учреждение высшего образования "Новосибирский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО НГМУ Минздрава России) Способ выявления предраковых изменений в молочной железе
RU2762317C1 (ru) * 2021-02-24 2021-12-17 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Способ прогнозирования статуса рецептора эпидермального фактора роста her2/neu в основном опухолевом узле у больных раком молочной железы
CN115044590B (zh) * 2022-06-30 2023-08-15 昆明理工大学 p53基因突变体及其表达的蛋白在制备诊断和治疗肥厚型心肌病的药物中的应用

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031882A1 (en) * 1993-06-15 2001-10-18 Serhan Charles N. Lipoxin compounds and their use in treating cell proliferative disorders
US20030198970A1 (en) * 1998-06-06 2003-10-23 Genostic Pharma Limited Genostics
US20040037842A1 (en) * 2000-03-24 2004-02-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20040142389A1 (en) * 1998-11-19 2004-07-22 O'mahony Daniel Joseph Antibodies to peptides that target GIT transport receptors and related methods
WO2004108899A2 (en) * 2003-06-04 2004-12-16 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Pni microarray and uses
US20050287127A1 (en) * 2003-11-13 2005-12-29 Huawei Li Use of stem cells to generate inner ear cells
WO2006002433A2 (en) * 2004-06-24 2006-01-05 Veridex, Llc Methods and reagents for the detection of melanoma
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20060211008A1 (en) * 2004-09-22 2006-09-21 Perry Mongroo Beta-parvin expression for use in diagnostic methods for assessment of breast cancer
US20070010469A1 (en) * 2000-06-02 2007-01-11 Chan Vivien W Gene products differentially expressed in cancerous cells III
US20070166728A1 (en) * 2005-07-22 2007-07-19 Alphagenics, Inc. Genetic profile imaging and data-sharing device and methodology for socially relevant traits

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6528054B1 (en) * 1998-12-28 2003-03-04 Corixa Corporation Compositions and methods for the therapy and diagnosis of breast cancer
GB9903841D0 (en) * 1999-02-20 1999-04-14 Imp College Innovations Ltd Diagnosis and treatment of cancer
DE60200248T2 (de) * 2002-08-01 2005-01-27 Mtm Laboratories Ag Verfahren für Lösung-basierte Diagnose
EP1907858A4 (en) * 2005-06-13 2009-04-08 Univ Michigan COMPOSITIONS AND METHODS OF TREATMENT AND DIAGNOSIS OF CANCER
US20070099209A1 (en) * 2005-06-13 2007-05-03 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
CN101970685B (zh) * 2007-01-16 2013-08-07 Musc研究发展基金会 诊断前列腺疾病的试剂盒
RU2340896C1 (ru) * 2007-05-17 2008-12-10 Негосударственное научно-исследовательское учреждение "Биомедицинский центр" Способ диагностики онкологических заболеваний

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010031882A1 (en) * 1993-06-15 2001-10-18 Serhan Charles N. Lipoxin compounds and their use in treating cell proliferative disorders
US20030198970A1 (en) * 1998-06-06 2003-10-23 Genostic Pharma Limited Genostics
US20040142389A1 (en) * 1998-11-19 2004-07-22 O'mahony Daniel Joseph Antibodies to peptides that target GIT transport receptors and related methods
US20040037842A1 (en) * 2000-03-24 2004-02-26 Corixa Corporation Compositions and methods for the therapy and diagnosis of colon cancer
US20070010469A1 (en) * 2000-06-02 2007-01-11 Chan Vivien W Gene products differentially expressed in cancerous cells III
WO2004108899A2 (en) * 2003-06-04 2004-12-16 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Pni microarray and uses
US20060019256A1 (en) * 2003-06-09 2006-01-26 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20050287127A1 (en) * 2003-11-13 2005-12-29 Huawei Li Use of stem cells to generate inner ear cells
WO2006002433A2 (en) * 2004-06-24 2006-01-05 Veridex, Llc Methods and reagents for the detection of melanoma
US20060211008A1 (en) * 2004-09-22 2006-09-21 Perry Mongroo Beta-parvin expression for use in diagnostic methods for assessment of breast cancer
US20070166728A1 (en) * 2005-07-22 2007-07-19 Alphagenics, Inc. Genetic profile imaging and data-sharing device and methodology for socially relevant traits

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Buck et al., Biotechniques, vol. 27, pages 528-536, 1999. *
Lowe et al. Nucleic acids research, vol. 18, no. 7, pages 1757-1761, 1999. *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013085482A1 (en) * 2011-12-05 2013-06-13 Phigenix, Inc. Compositions and methods for monitoring and detecting cancerous conditions
CN115724966A (zh) * 2022-08-22 2023-03-03 北京中杉金桥生物技术有限公司 一种抗人配对盒基因2兔单克隆抗体、制备方法及其应用

Also Published As

Publication number Publication date
AU2009351638B2 (en) 2016-03-31
CN102648287A (zh) 2012-08-22
US20130023424A1 (en) 2013-01-24
EP2475779A1 (en) 2012-07-18
AP2012006182A0 (en) 2012-04-30
AP3331A (en) 2015-07-31
HK1174955A1 (en) 2013-06-21
US20130023425A1 (en) 2013-01-24
WO2011025475A1 (en) 2011-03-03
JP2013510558A (ja) 2013-03-28
RU2012111372A (ru) 2013-10-10
EP2475779B1 (en) 2014-05-14
CA2771993A1 (en) 2011-03-03
US8722367B2 (en) 2014-05-13
ZA201202170B (en) 2012-11-28
US8623617B2 (en) 2014-01-07
IL218285A0 (en) 2012-04-30
CN102648287B (zh) 2015-03-04
RU2522485C2 (ru) 2014-07-20
NZ599004A (en) 2014-04-30
AU2009351638A1 (en) 2012-04-19
IL218285A (en) 2017-08-31
AU2009351638A2 (en) 2012-05-03
JP2016000041A (ja) 2016-01-07
EP2475779A4 (en) 2013-03-13

Similar Documents

Publication Publication Date Title
US8623617B2 (en) Detecting PAX2 for the diagnosis of breast cancer
US12064403B2 (en) Targeting PAX2 for the treatment of breast cancer
EP3055429B1 (en) Method for the prognosis and treatment of metastasizing cancer of the bone originating from breast cancer
EP2470217B1 (en) Targeting pax2 for the treatment of breast cancer
JP5990274B2 (ja) 前立腺病態の処置のためのｅｎ２、ｐａｘ２、および／またはｄｅｆｂ１の標的化
US20140323349A1 (en) Compositions and methods for monitoring and detecting cancerous conditions
US20120071347A1 (en) Compositions and methods for monitoring and detecting cancerous conditions
Xiao et al. MiR-144-3p regulates invasion and proliferation activity in hepatocellular carcinoma by targeting SLITRK4

Legal Events

Date Code Title Description
AS Assignment

Owner name: PHIGENIX, INC.,GEORGIA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DONALD, CARLTON D.;REEL/FRAME:023185/0040

Effective date: 20090831

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

AS Assignment

Owner name: MUSC FOUNDATION FOR RESEARCH DEVELOPMENT, SOUTH CA

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:MEDICAL UNIVERSITY OF SOUTH CAROLINA;REEL/FRAME:033091/0328

Effective date: 20080123

Owner name: MEDICAL UNIVERSITY OF SOUTH CAROLINA, SOUTH CAROLI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DONALD, CARLTON D.;REEL/FRAME:033091/0182

Effective date: 20080111